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CHAPTER 1. GENERAL INTRODUCTION 
INTRODUCTION 
 Influenza A virus (IAV) is a member of the family Orthomyxoviridae and is 
considered a major pathogen for a number of species including humans, swine, and avian 
species. Historically, the potential of avian and swine influenza A viruses, either through 
direct infection by intact virus or through incorporation of genetic information into 
human isolates, have presented major zoonotic risks to human health risks with epidemic 
and pandemic potential (98). Prior to the 2009 pandemic, experts were concerned that 
high pathogenic avian IAV, particularly H5N1, was going to become established in the 
human population and that such establishment would lead to a pandemic crisis due to the 
lack of human population immunity to the avian IAV (24, 96). One hypothesized 
mechanism by which avian IAV could establish itself in the human population is through 
adaptation in an intermediate host, such as a pig (50). Because such a possibility may 
exist, determination of the prevalence of H5N1 infection in the swine populations in 
regions endemic for highly pathogenic H5N1 viruses is highly desirable. 
 Though the inherent pathogenicity of an intact wildtype virus for its natural host 
is evident in field or experimental infections, incorporation of the genetic factor(s) 
responsible for pathogenicity from one virus to another may result in disease that is just 
as severe. One such pathogenicity factor is the PB1-F2 protein found in a secondary open 
reading frame of the PB1 mRNA. The PB1-F2 protein is relatively small when compared 
to other influenza proteins but is associated with a number of pathogenicity factors, 
including apoptosis, immunopathology, and secondary bacterial infection (23, 63, 105). 
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Though a fair amount of work has been done to understand PB1-F2 in human and avian 
isolates, currently little is known about the function and expression levels of PB1-F2 
during infection with swine influenza virus isolates. Given the zoonotic potential of 
swine influenza viruses, it is important to understand the effect that PB1-F2 could have 
on both human and animal health. 
THESIS ORGANIZATION 
 Following this introduction, this thesis consists of five additional chapters. 
Chapter 2 gives a general introduction into influenza A viruses and a brief introduction 
into methods of serological detection of influenza viruses. Chapter 3 describes 
development of a serological assay for detection of antibodies to H5N1 in swine serum 
samples. Chapter 4 details initial studies on the translational regulation of PB1-F2 in 
swine influenza viruses, the results of which are being prepared for publication in the 
Journal of Virology. Chapter 5 is a continuation of work in progress for the PB1-F2 
translation project. Chapter 6 provides a general conclusion for the projects described in 
Chapters 4 and 5. References are listed at the end of each chapter. 
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CHAPTER 2. REVIEW OF INFLUENZA A VIRUS VIRAL 
PROPERTIES, VIRAL INFECTION, AND DIAGNOSTICS 
INTRODUCTION 
 Influenza A virus (IAV) is a member of the Orthmyxoviridae family, which also 
includes Influenza B and C, Isavirus, and Thogotovirus. IAV is an enveloped virus 
comprised of an eight segmented negative sense single-stranded RNA [(-)ssRNA] 
genome, which can encode  up to thirteen viral proteins (51, 68, 74). These proteins 
include two surface glycoproteins, an ion channel protein, a nucleocapsid protein, a 
tripartite polymerase complex, a structural scaffolding protein, two non-structural 
proteins, and three non-essential proteins (74). Historically, IAV isolates have been 
categorized and referenced serologically subtypes by their different glycoproteins, 
hemagglutinin and neuraminidase. However, with the advent of sequencing technology 
has allowed further sub-categorization of viruses within the previously defined subtypes 
through relative nucleic acid homology (94). To date, a total of seventeen hemagglutinin 
and nine neuraminidase proteins have been described (100). Interestingly, while all three 
genera of influenza viruses manifest as similar diseases in humans, infection by influenza 
A is more common, more frequently severe, diverse in host specificity, and the only type 
known to cause pandemic level infections (74). 
 In modern recorded history, IAV infection earned its place as a major human 
respiratory pathogen during the 1918 H1N1 influenza pandemic, also known as the 
"Spanish" flu pandemic (7, 56, 98). Considered to be the worst influenza pandemic in 
recorded history, the 1918 pandemic was responsible for over 20 million deaths and 
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countless numbers of infected and hospitalized individuals (98, 99). The pandemic was 
believed to have been the result of zoonotic transmission of an avian virus to a human 
host, which had adapted and then rapidly spread (99, 102). During this time, pigs also 
were infected with the 1918 H1N1 virus and some have postulated that they, too, may 
have played a role in the spread of the deadly pandemic virus (56, 99). 
 Since the 1918 pandemic, IAV has remained as a major respiratory pathogen 
detrimental to human and animal health, even with the inception of effective vaccine 
strategies and antiviral drugs. This persistence is likely the result of two evolutionary 
mechanisms used by IAV to thwart host defensive mechanisms and adapt to the host 
environment. Antigenic drift refers to the mutagenesis of IAV proteins during the natural 
replication process of the virus that may allow variant to survive or outcompete in the 
presence of selective pressures resulting in the survival of antigenically novel proteins 
and drug resistant IAV isolates (16, 87). Antigenic shift is the development of IAV 
isolates with novel surface glycoprotein combinations through recombination of gene 
segments from two or more parental isolates as a result of the superinfection of a host by 
multiple viruses, a process also known as reassortment (11, 15, 22, 67). One virus that is 
thought to be the result of multiple reassortment events is the recent 2009 H1N1 
pandemic virus (69). 
 The emergence of the 2009 H1N1 swine-derived pandemic virus (H1N1pdm09) 
illustrates that the damages associated with influenza pandemics is not only isolated to 
the pathogenicity and mortality, but also costly socioeconomic implications. The 2009 
pandemic virus is the result of reassortment events involving viruses that encode genes 
for HA, PA, PB1, PB2, NP, and NS proteins that share sequence homology with North 
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American triple-reassortant swine isolates and the NA and M sequences that are more 
similar to an Eurasian avian-like swine influenza viruses (69). Prior to the 2009 
pandemic, this specific combination of swine IAV gene segments had never been 
reported in a swine population (58). The first cases of H1N1pdm09 were reported to the 
World Health Organization (WHO) on March 23, 2009. By the following mid-June, 
WHO declared H1N1pdm09 as the first pandemic of the 21st century and within a single 
year (April 2009-2010) an estimated 61 million cases of H1N1pdm09 occurred in the 
U.S. alone (17). In contrast to seasonal IAV in humans, H1N1pdm09 pathogenicity 
appeared to be more severe than was expected in younger infected individuals and less 
severe than was expected in the elderly population, which appeared to have preexisting 
immunity to an antigenically similar historical human IAV isolate (114, 115). Because of 
the high transmissibility of the virus, atypical demographics, and apparent increase of 
mortality during the second wave of infection, panic for the need of both IAV 
therapeutics and vaccines developed, along with the fear of infection, which had an 
overreaching effect on the economy (17). Either as a result of therapeutic development or 
a result of preexisting immunity, the 2009 IAV isolates were less severe pathogen in 
comparison to the 1918 pandemic isolate (17). Together the 1918 and 2009 IAV 
pandemics illustrate the shear havoc IAV can produce on both human and socioeconomic 
health, as well as its zoonotic potential, demanding a proper understanding of this viral 
threat. 
HISTORY OF SWINE INFLUENZA VIRUS 
 The first descriptions of IAV-like illness in pigs coincided with the 1918 
pandemic, but IAV was not isolated from pigs until 1930 (92). This virus and the nearly 
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identical virus subsequently isolated from humans served as the prototype type A, 
subtype H1N1 virus. The swine H1N1 virus, commonly referred to as classical swine 
H1N1 (cH1N1), remained the predominant strain in North American pig populations for 
nearly seven decades. In 1998, a novel H3N2 virus emerged that contained HA, NA, and 
PB1 gene segments from human virus lineage, the M, NP, and NS from classical swine 
H1N1, and the PA and PB2 from avian virus lineage. Thus, it is referred to as a triple 
reassortant because of the virus's genetic makeup (52, 120). Establishment of the H3N2 
triple reassortant would later aid in the diversification of swine IAV through the 
acquisition of hemagglutinin and neuraminidase due to further reassortment with cH1N1 
swine IAV and human seasonal viruses. However, the remaining six segments remain a 
commonality between the 
viruses (67). To date, triple 
reassortant viruses are the 
dominating strains 
circulating in the swine 
population. 
INFLUENZA VIRION 
 An infectious 
influenza viral particle 
consists of either a spherical 
or pleomorphic lipid bilayer 
membrane that contains eight 
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viral ribonucleoprotein complexes (vRNPs) (Fig. 1; (74)). On its surface, there are three 
membrane-bound proteins including hemagglutinin, neuraminidase, and matrix 2. By 
proportion, 80% of the surface proteins are hemagglutinin, around 17% are 
neuraminidase, and the remaining three percent is matrix 2 (65, 90). Directly underneath 
the lipid bilayer is a scaffold of matrix 1 protein that connects the surface proteins and 
vRNPs, which provides the overall structure for the viral particle. All of this is used to 
house the eight vRNPs that consist of negative sense RNA completely bound by 
nucleoprotein with the tripartite polymerase complex on the 3ʹ terminus of the viral RNA 
(93). 
STRUCTURAL VIRAL PROTEINS 
Hemagglutinin: receptor binding protein 
 The hemagglutinin (HA) protein serves as the viral receptor binding protein for 
viral attachment and fusion protein for entry (93). During viral infection, the HA protein 
is translated and bound to the endoplasmic reticulum (ER) membrane, then processed in 
the Golgi, and lastly, transported to the apical surface of the infected cell using the 
exocytic transport machinery where it localizes to lipid rafts (19, 93). Three copies of the 
hemagglutinin protein will then combine to form a homotrimeric glycoprotein complex 
which serves as the receptor for IAV. The initial protein translated by the HA mRNA is a 
precursor commonly referred to as HA0 and requires proteolytic cleavage in order to 
form the final subunits HA1 and HA2. Cleavage of the HA precursor primarily occurs 
when the protein is exposed to endogenous proteases, such as trypsin-like proteases, and 
results in a conformational change that is necessary for proper protein function (93). 
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However, in instances in which the HA contains a polybasic cleavage site, such as the 
case in highly pathogenic avian influenza viruses, the HA precursor can be cleaved 
through the use of a furin-like protease commonly found in the Golgi apparatus (39). 
Upon cleavage, the HA1 and HA2  domains remain in contact through disulfide-bonds 
(93). 
 HA1 and HA2 domains each possess important functions for viral entry into 
susceptible cells. HA1 forms a globular head structure on the end of the hemagglutinin 
protein and is responsible for the attachment of the virus to sialic acid residue 
modifications of host cell glycoproteins. Therefore, the HA1 domain is also responsible 
for establishing the preference for either α-2,3 sialic acid receptors or α-2,6 sialic acid 
moieties on host receptors. Typically, a preference for α-2,3 sialic acid receptors is 
associated with avian influenza isolates, while human and a number of other mammalian 
influenza isolates prefer α-2,6 sialic acid receptors (30). Notably, this is not necessarily 
always the case (4). In addition to serving as the stalk, keeping the HA receptor 
embedded in the envelope of the virion, the HA2 domain also serves an important 
function in viral entry as the viral fusion protein between the viral and endosomal 
membranes upon proteolytic cleavage (93). The process for viral fusion will be described 
later in this thesis in detail. 
Neuraminidase: viral sialidase glycoprotein 
 The IAV neuraminidase (NA) protein belongs to a class of glycoside hydrolases, 
also known as sialidases, and is necessary for the removal of sialic acid residues from 
both glycoproteins and glycolipids on the surface of infected cells and newly formed viral 
particles (75). Similar to HA protein, the NA protein is translated in and embedded in the 
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membrane of the ER and is transported to lipid rafts through the exocytic pathway. In its 
final form, the NA protein is a homotetramer comprised of four NA subunits (19). The 
sialidase activity of NA is necessary for budding of new viral particles from infected cells 
and does this by removing sialic acid residues from glycoproteins and glycolipids on the 
surface of the host cells to prevent the virus from reattaching to the cell (75). 
Additionally, the NA protein is also responsible for removing sialic acid residues from 
the virion, which is necessary for preventing viral particles from binding to each other 
and forming aggregates (75). 
Matrix 2: proton ion channel 
 Matrix 2 (M2) protein is a homotetramer, which is translated from a spliced RNA 
product of the matrix 1 mRNA (3). M2 is also translated in the ER and transported to the 
apical plasma membrane. However, unlike HA and NA, M2 does not associate with lipid 
rafts, but it contains a cholesterol binding domain that is believed to keep M2 in 
proximity of the lipid rafts (19, 90). M2 serves as a proton ion channel that is necessary 
for priming the internal components of the viral particle for entry into the cytoplasm after 
viral entry and plasma membrane fusion, which will be described in detail later. 
Matrix 1: Scaffolding protein 
 The matrix 1 (M1) protein has significant roles in establishing the virion assembly 
sites, nuclear export of viral ribonucleoprotein complexes, and viral budding (5, 71, 85, 
88). After translation in the cytoplasm, M1 proteins localize at either the apical plasma 
membrane or the nucleus (5). Localization of M1 at the apical plasma membrane is 
thought to occur through interactions of M1 with lipids and the cytoplasmic exposed 
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portions of HA, NA, and M2; thus allowing for M1 to travel along with the exocytic 
membrane vesicles (65, 85, 88). Once at the apical plasma membrane, M1 protein 
subunits will begin to interact with each other through M1-M1 interaction sites to form a 
scaffolding matrix for assembly of new viral particles (19, 71). The interactions with both 
the surface proteins and other M1 subunits both result in bringing the three surface 
proteins of the influenza viral particles closer together and in defining areas where the 
influenza particle will assemble and bud from the cell (19, 90). If the M1 monomers do 
not interact with the viral glycoproteins, the M1 protein will localize at the nucleus 
through its nuclear localization signaling (NLS) sequence. Here M1 will interact with the 
vRNPs and nuclear export protein (NEP), which will allow for export of vRNP-M1-NEP 
complexes (2, 60, 71). Nuclear export of vRNPs will be covered later in the viral 
lifecycle portion of the thesis.  
Viral ribonucleoprotein complex associated proteins 
 Viral ribonucleoprotein complexes (vRNPs) refer to the replicative units that are 
comprised of a single segment of RNA and the bound proteins: including nucleocapsid 
protein (NP), polymerase basic protein 1 and 2 (PB1 and PB2, respectively), and 
polymerase acidic protein (PA) (55). vRNPs are necessary for the transcription of viral 
mRNA, complementary RNA (cRNA), and viral genomic RNA (vRNA) and, pending on 
the RNA molecule being transcribed, can either contain negative sense vRNA molecule, 
used for mRNA and cRNA transcription, or cRNA molecule, used for vRNA 
transcription(42). All four proteins have necessary roles to play and interact to complete 
all the intricate steps necessary for transcription and replication of the RNA genome. 
Because IAV is an unique RNA virus in that it replicates in the nucleus, all four proteins 
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contain NLS sequences to allow them to be transported to the nucleus after translation in 
the cytoplasm (reviewed in(10)). However, the polymerase subunits trimerize in the 
cytoplasm prior to nuclear localization (34). 
 As the nucleocapsid protein, NP's primary role is to protect the vRNA and cRNA 
from RNA degradation. To facilitate this function, NP proteins encapsulate the entire 
RNA molecule, which stabilizes and protects the RNA in the host environment (26). NP 
also plays a role in export of vRNPs and is theorized to play a role in the switch from 
protein translation to viral replication, both will be explained in detail later (84). 
 PB1, PB2, and PA interact to form the IAV three subunit heterotrimer RNA-
dependent RNA polymerase (RdRp), which occurs shortly after being translated in the 
cytoplasm (34). Out of the three subunits since it has a larger number of responsibilities 
when it comes to the RdRp activity. Among those responsibilities, the PB1 protein is the 
only subunit known to possess the enzymatic polymerase activity necessary for RNA 
replication, but also has specific regions for vRNA recognition, cRNA recognition, PB2 
interaction, and PA interaction (42). The PB2 proteins main role is for the recognition of 
7-methylguanosine cap on host mRNA, which is then removed through the endonuclease 
activity of the PA protein and used for priming of IAV mRNA (8, 9, 31, 79, 103). The 
removal and use of the host RNA cap for mRNA priming is commonly referred to as 
"cap-snatching" and, as a byproduct, downregulates host mRNA translation. 
NON-STRUCTURAL VIRAL PROTEINS 
Non-structural protein 1:  host cell antagonist 
 Non-structural protein 1 (NS1) has been attributed to a plethora of functions 
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associated with inhibiting host cellular translational and innate immunity at the cellular 
level. NS1 binds to cleavage and polyadenylation specific factor (CPSF) protein and 
prevents the polyadenylation of host cell mRNA to interfere with host translation (91). 
Additionally, NS1 has also been shown to interact with eukaryotic initiation factor 4G 
(eIF4G), associated with enhancing mRNA cap recognition, to promote viral translation 
through recruitment of eIF4F, cap recognition protein (13). In combination with PA and 
PA-X, described later, endonuclease activities and the interaction of NS1 with eIF4Fs 
aids to decrease host cellular mRNA translation while promoting viral mRNA translation 
(13, 31, 51). This trend of inhibiting host cellular translation while promoting viral 
mRNA translation also occurs through NS1's interaction with U6 small nuclear RNA and 
splicesomal components. This interaction results in the recruitment of the spliceosome in 
the nucleus of infected cells inhibiting host cell mRNA splicing and promoting viral 
mRNA splicing, which is necessary for splicing of M1 and NS1 mRNA in order to 
translate M2 and NEP, respectively (109).  
 Though NS1's role in translation aids in viral replication, its role in inhibiting 
innate immunity is necessary for viral replication, as viral mutants lacking NS1 are 
replication deficient in interferon expressing cells (37). This is accomplished through a 
number of redundant mechanisms in order to ensure that efficient viral replication is 
possible. First, NS1 binds to TRIM25 inhibiting ubiquitination of retinoic acid-inducible 
gene I (RIG-I) and downstream signaling of the interferon (IFN) pathway (38). This 
pathway is further inhibited through direct interaction of NS1 with viral dsRNA, products 
of secondary structures, and with viral (-)ssRNA free 5ʹ triphosphates to prevent their 
recognition from RNA pattern recognition proteins including RIG-I, melanoma 
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differentiation-associated protein 5 (MDA-5), and protein kinase R (PKR)(59, 97). 
Inhibition of PKR prevents the cellular stress response from downregulating translation. 
The blockage of vRNA recognition has also been associated with an interaction with the 
human homologue of Staufen (hStaufen), and interaction with hStaufen may aid in 
sequestering viral mRNAs to polyribosomal sites (36). Lastly, NS1 is associated with 
inhibition of caspase-1 dependent pathways which prevents maturation of proper 
interleukin responses and caspase-1 dependent apoptotic pathways (95).  
Nuclear export protein 
 Nuclear export protein (NEP), also referred to as NS2, is translated as a result of a 
spliced product of the NS1 mRNA (3). NEP, as its name suggest, is necessary for the 
nuclear export of newly formed vRNPs, which are transported to assembly sites at the 
apical plasmid membrane. To facilitate this function, NEP is able to bind to M1, which as 
described earlier binds to vRNPs and CRM1, a host nuclear export protein to allow for 
the export of newly formed vRNPs using the host's machinery (2, 10, 68). Interestingly, 
NEP does not possess a NLS sequence to aid in facilitating its function, but is believed 
diffuse freely into the nucleus due to its small size, approximately 14.5 kDa (68). 
NON-ESSENTIAL VIRAL PROTEINS 
 The IAV genome encodes three proteins that are considered to be non-essential 
for replications, which include PB1-F2, N40, and PA-X (23, 51, 112). Though they are 
considered non-essential, depending on the IAV strain all three proteins possess 
properties that may dramatically alter the effect of viral infection with regards to viral 
replication, viral pathogenicity, and modulation of host cell signaling. Interestingly, all 
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three of these proteins share the commonality of being an alternate translational product 
of an IAV polymerase mRNA, either from PB1 or PA, as a result of non-canonical viral 
translation (17, 28, 59). 
Non-canonical translation motifs of IAV non-essential proteins 
 Normal translation of eukaryotic proteins is initiated through the binding of both 
the mRNA 7- methylguanosine cap and poly(A) tail by eukaryotic initiation factor 4E 
(eIF4E) and poly(A) binding protein (PABP) (Fig. 2A). After eIF4E and PABP bind to 
the mRNA, both proteins then bind to eIF4G resulting in the formation of the 
translational loop to facilitate the interaction between the 40S ribosomal subunit and the 
mRNA. After the 40S ribosomal subunit and associate eIFs recognize the initial start 
codon, the eIF proteins are released and the 60S ribosomal subunit and eukaryotic 
elongation factors eEFs are recruited followed by translation of the encoded protein. 
Translation will proceed until the identification of a stop codon occurs; resulting in the 
recruitment of eukaryotic release factors that halt translation and promote the dissociation 
of the ribosomal subunits from the mRNA (reviewed in detail in (108)). This simplified 
version illustrates the complexities involved in eukaryotic translation of mRNA. 
Therefore, it is impressive that viruses have developed non-traditional, or non-canonical, 
translational motifs in order to make greater use of limited genetic makeup. IAV uses two 
different forms of non-canonical translation motifs for translation of its non-essential 
proteins, including leaky ribosomal scanning and +1 frameshifting (23, 51, 112). 
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 Translation of PB1-F2 and N40 are the result of leaky ribosomal scanning (LRS) 
of the PB1 mRNA (Fig. 2B). LRS occurs during the initial scanning of the mRNA by the 
40S ribosomal complex in which the translational machinery will bypass start codons 
with weaker Kozak sequences, which are less preferable surrounding sequences, and will 
initiate translation downstream of the initial start codon, potentially at a stronger Kozak 
sequence (23, 112). In the case of the PB1 mRNA, the translation machinery must bypass 
the first three start codons for translation of PB1-F2 and the first four start codons in 
order to translate N40. Both PB1-F2 and N40 possess strong Kozak sequences while the 
first three have weak to moderate Kozak sequences. As would be expected, translation of 
PB1-F2 and N40 through LRS PB1 is limited as translation of the full-length PB1 is 
necessary for viral replication (112). 
 The second method of non-canonical translation is +1 frameshifting during 
translation of the PA mRNA, which results in translation of PA-X. +1 frameshifting 
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occurs through a "slippage" of the mRNA in the ribosome which results in shifting the 
nucleic acid codon sequences in the 3ʹ direction by a single nucleotide. In the case of the 
PA mRNA, the ribosome encounters a 5ʹ-UCCUUUCGUC-3ʹ motif, a common sequence 
in low frequency frameshifting. While binding to the anticodon for the UUU codon, 
"slippage" of the mRNA occurs and the anticodon instead binds to the UUC, which has a 
higher affinity for the phenylalanine tRNA. The resulting protein contains the N-terminal 
endonuclease domain of PA and the X-ORF domain that is typically 61 amino acids in 
length, hence the name PA-X (51). 
PB1-F2: proapoptotic membrane associated protein 
 Encoded in the PB1 mRNA are two of the three non-essential proteins. The first 
was discovered in a second open reading frame (ORF) of the PB1 mRNA and thus named 
PB1-F2 (23). Since the initial discovery of PB1-F2, a number of pathogenicity effects 
have been attributed to PB1-F2 interaction with host mechanisms including induction of 
apoptosis, immunopathology, and secondary bacterial infection (23, 29, 106, 111, 117). 
However, it has also been associated with increasing viral replication through an 
interaction with PB1 (61). 
 A pivotal role attributed to expression of PB1-F2 was the induction of the 
intrinsic apoptotic pathway, which means: the induction of apoptosis through the 
permeabilization of the mitochondria and the release of cytochrome C (116, 117). For 
PB1-F2, there are two possible scenarios in which it can induce apoptosis: 1) through an 
interaction with mitochondrial associated channels (40, 117)and 2) through the 
oligomerization of PB1-F2 forming non-selective pores (12, 18, 44). For the first 
mechanism, PB1-F2 has been described to interact with inner mitochondrial protein 
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adenine translocator 3 (ANT3) and outer mitochondrial protein voltage-dependent anion 
channel 1 (VDAC1) which results in the formation of a pore and the release of 
cytochrome C (116, 117). The other is through self-oligomerization of PB1-F2 to form 
non-selective pores that insert and permeabilize the membranes, such as the 
mitochondrial membrane. However, though PB1-F2 self-oligomerization has been shown 
in biochemical assays, it has not been detected in infections (12, 18, 44). It is noteworthy 
to mention that recently the apoptotic function of PB1-F2 has come under a great amount 
of scrutiny and some  research suggests the function only occurs with a rare number of 
isolates (20). 
 Another major role attributed to PB1-F2 associated with PB1-F2 is modulation of 
both the innate interferon (IFN), and cell-mediated immune response (CMI) (23, 25, 33, 
62, 106). PB1-F2 antagonizes the intracellular IFN pathway through a direct interaction 
with mitochondrial antiviral signaling protein (MAVS), an essential mediator protein for 
transcriptional upregulation of IRF and NF-κB signaling pathways (27, 106). 
Interestingly, where PB1-F2 antagonizes the IFN pathway, it also promotes a 
proinflammatory CMI response through cytokine dysregulation resulting in the 
neutrophil infiltration of the lungs and a more severe pneumonia (25, 33, 64). This 
promotion of a proinflammatory state also appears to promote, or coincide with, a 
secondary bacterial infection and has been shown to increase the damaging effects of 
influenza and bacterial co-infection (63, 111). 
 Although, PB1-F2 has been associated with an increase in pathogenicity, it is not 
actually necessary for viral replication, and the functions associated with PB1-F2 
expression appear to be strain specific and, therefore, full-length open reading frames for 
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PB1-F2 are not always present in IAV isolates. This difference or lack of function of 
PB1-F2 may be associated with regulation of PB1-F2 expression, which is a topic that 
will be discussed further in the thesis. 
N40: viral transcriptional regulator 
 As stated earlier, N40 is the second translation product that results from LRS of 
the PB1 mRNA and occurs in the same ORF as the PB1 protein, but is initiated forty 
amino acids downstream of the PB1 start codon. Therefore, it is not surprising that N40 
interacts with PB2 and PA, but N40 does not possess polymerase activity and, to my 
knowledge, has not been shown to interact with either of the viral RNA molecules, vRNA 
or cRNA. According to Wise et al., the function of N40 is primarily associated with 
maintaining balance between PB1 and PB1-F2 expression to maintain favorable 
replication levels. They showed that inhibition of N40 expression in the presence of PB1-
F2 expression results in delaying viral replication, but removal of both PB1-F2 and N40 
resulted in no change. Thus, N40 is not necessary for viral replication, but it is beneficial 
as a balancing mechanism to maintain viral transcription in certain viral strains (112). 
PA-X: host signaling antagonist 
 Discovered in 2012, PA-X is the newest addition to the described IAV encoded 
protein and is predicted to be encoded in a majority of IAV isolates. As stated earlier, 
PA-X is the resulting product of a +1 frameshift from translation of the PA mRNA and 
possesses the N-terminal endonuclease portion of PA and a novel X-ORF amino acid 
coding sequence. Functionally PA-X has been shown to globally repress cellular gene 
expression by specifically targeting host cell mRNA with its endonuclease activity. 
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Notably, Jagger et al. showed that downregulation of gene expression through 
endonuclease activity was primarily associated with PA-X instead of PA. While this 
protein is considered to be non-essential because it is not necessary for replication, loss of 
PA-X resulted in a stronger host response to IAV infection (51). 
IAV INFECTION LIFE CYCLE 
 Initial exposure and infection with IAV occurs through either direct contact with 
an infected host or viral containing aerosolized droplets which enter the body through 
nasal or oral routes (74). Upon entry into the host, IAV particles bind to host receptors 
through HA binding sites with their preferential sialic acid receptor, generally α-2,3 sialic 
acid receptor for avian IAV isolates or α-2,6 sialic acid for human and mammalian IAV 
isolates (30). IAV entry into the cell has been shown to take advantage of a number of 
endocytotic pathways, but de novo experiments suggest IAV preferentially enters through 
clathrin-coated pits (86). While in the endosome, IAV undergoes a number of 
confirmation changes in response to the decrease in pH including a confirmation change 
in HA that allows the HA2 subunit to imbed into the lipid membrane of the endosome, 
which then promotes fusion of the viral membrane with the endosome membrane by 
mechanically pulling the two closer together (93). The decrease in pH is also necessary 
for priming the vRNPs through dissociation of the M1 scaffolding matrix, freeing the 
vRNPs for entry into the cytoplasm. The drop to a pH of 5 is facilitated by M2 by 
allowing entry of protons into the viral core (80). After priming and fusion, the vRNPs 
enter the cytoplasm and are transported to the nucleus through an interaction of NP with 
the importin α/β pathway. However, notably the viral proteins associated with vRNPs 
contain nuclear localization signals that have been speculated to contribute to import (72, 
21 
 
113). 
 After entry into the nucleus, the vRNPs begin initial translation of all the viral 
proteins. Initiation of IAV mRNA transcription occurs through sequestration of the 7-
methyguanosine (7-m) caps from host mRNA by PB1 and PA endonuclease activity from 
which the 7-m cap is then used for priming of viral mRNA (8, 31). After transcription, 
the viral mRNA is polyadenylated through a "stuttering" mechanism in which the viral 
polymerase encounters a poly-uracil region approximately 17nt from the 5ʹ end of the 
vRNA and transcribes back and forth over the poly-uracil region until the poly-(A) tail is 
completed (82). mRNA products are then transported to either ER-associated ribosomes 
(HA, NA, and M2) or cytoplasmic ribosomes (all other viral proteins) for translation. 
 The mechanism for the temporal transition from viral protein translation to viral 
replication is still largely unknown. However, it has been theorized that accumulation of 
either M1 or NP may be factors in the transition to replication (60, 83). It should be noted 
that transcription of viral mRNA, cRNA, and vRNA occurs throughout the viral life 
cycle, but transcriptional levels of the RNA molecules vary temporally (53). No matter 
the circumstance, initiation of replication results in the transcription of the intermediate 
cRNA and newly transcribed genomic vRNA through a self-priming secondary structure 
in the UTR sequence. Immediately after transcription, the newly formed cRNA and 
vRNA molecules are encapsulated by NP to stabilize the RNA molecules and are bound 
to the tripartite polymerase to form new RNP complexrd (55). Nuclear localized M1 then 
binds to vRNPs through NP and NEP, which in turn binds to CRM1 resulting in the 
exportation of vRNPs to the cytoplasm. vRNPs then localize at the recycling endosome 
and the viral polymerase of the vRNPs then interacts with Rab11 resulting in the 
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transport of vRNPs to the apical plasma membrane (2, 68). 
 vRNPs then interact with the M1 scaffolding of virion assembly sites located at 
the apical plasma membrane. Budding of IAV particles occurs through a cholesterol-
dependent manipulation of the membrane by an amphiphatic helical domain located in 
M2, providing a unique endosomal sorting complex required for transport (ESCRT)-
independent mechanism for IAV budding (85). Prior to or during release, the NA protein 
removes sialic acid modifications from glycoproteins and glycolipids on the surface of 
the cell and virion, allowing for efficient viral release and preventing the formation of 
virion aggregates (75). IAV virions are then released into the respiratory lumen where 
they will go on to either infect other cells within the host or be released into the 
environment to infect a new host (74). 
BASIC PRICIPLES OF SEROLOGICAL DETECTION OF INFLUENZA A 
INFECTION 
Hemagglutination and neuraminidase inhibition assays 
 Two oldest methods for serological detection of IAV infection, hemagglutination 
and neuraminidase inhibition assays, take advantage of functions associated with the 
surface glycoproteins of IAV viruses, and the hemagglutinin inhibition (HI) assay is still 
routinely used today for diagnostic purposes (46, 104). Because the HA protein has a 
high affinity for binding to sialic acid moieties, modified glycoproteins and glycolipids, 
IAV can be incubated with red blood cells (RBCs), which are rich in sialic acid 
modification on their surface, to form viral:RBC aggregates. This property can be used to 
determine hemagglutination units (HAU), which is the reciprocal of the last viral dilution 
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that forms aggregates with the RBCs of a viral isolate through a series of serial dilutions. 
HI assays are usually conducted with a standardized virus concentration between 4 and 8 
HAU/ml, and incubation with serial dilutions of antibody serum to form viral:antibody 
moieties. If enough antibodies are present, hemagglutination is inhibited. The reciprocal 
of the highest dilution of serum that can inhibit hemagglutination is the HI titer (46). In 
principle, NA assays and NA inhibition assays are the same except, instead of RBCs, 
substrates taking advantage of neuraminidases sialidase activity are used. Originally 
fetuin was used to measure neuraminidase activity and the sailidase activity could be 
quantified with downstream biochemical assays (104). ). The relatively simple HI assay 
has been used for many years as a standard serologic assay for measuring aniti-influenza 
antibody, both for diagnostic and for research purposes. Evaluation of new serologic 
assays usually involves comparison with measurement of antibody in the HI assay. The 
NA assay, which is technically more difficult, remains primarily a research tool and is 
seldom used for routine diagnostic work. 
Indirect enzyme-linked immunosorbent assays 
 The enzyme-linked immunosorbent assays (ELISAs) can be designed to detect 
antigens or antibodies with enzyme-conjugated antibodies. The serological assays 
described below in brief briefly are reviewed in detail in Crowther, J. R ELISA: Theory 
and Practice (121). An indirect ELISA can be used to detect antibody because the 
enzymatic activity that produces a color change in substrate resides in an enzyme protein 
attached to a secondary antibody that is directed against the antigen-specific antibody 
being measured (Fig. 3A). In its simplest form, an indirect ELISA uses antigen-coated 
plates that are incubated with test serum to form antigen:antibody complexes. Excess 
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antibodies are then washed away and a standard dilution of enzyme-conjugated antibody, 
or secondary antibody, is added and incubated to form serum antibody: secondary 
antibody complexes. After washing away the unbound secondary antibody, a substrate 
can be added, and the enzymatic activity on the substrate can be measured using 
absorbance, fluorescence, or luminescence, depending on the enzyme and substrate used. 
In this format, a higher signal is associated with a sample containing a higher antibody 
concentration. For the assay just described and those described below, it is necessary to 
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optimize the antigen concentration, test serum dilution, and conjugated antibody 
concentration to maximize the specificity and sensitivity of the assays. Specificity is the 
ability of the ELISA assays to determine that a true negative sample is negative and the 
sensitivity is the measurement of the ELISA the ability to determine that a true positive 
sample is positive. Because specificity and sensitivity can have an inverse relationship, 
manipulation of materials and methods is necessary to achieve an optimum balance 
between the two measurements of test efficacy. Advantages of the indirect ELISA 
include not requiring pathogen-specific enzyme-conjugated antibodies and being less 
labor intensive than the other two assays described later. However, compared to the 
blocking ELISA and competitive ELISA, described later, it has the disadvantage of cross-
reactive antibodies, not specific to the antigen, binding within the well providing false 
signals that decrease the specificity of the assay. To minimize cross-reactivity, high 
quality antigens are necessary for coating the plates. Alternatively, one of the following 
formats can help to improve the specificity. 
 To increase specificity of ELISA alternative platforms have been developed, two 
of which include the blocking indirect ELISA and the competitive indirect ELISA (Fig. 
3B and C). Both of these ELISA assays require the availability of antigen-specific 
enzyme-conjugated antibodies. In a blocking ELISA the steps are essentially the same as 
the previously mentioned ELISA, but instead of the conjugated antibody recognizing 
antibody in the serum it is targeted towards antigen bound to the bottom of the plate. 
With the competitive ELISA both the serum samples and the conjugated antibodies are 
added simultaneously and compete for antigen binding sites. In both the blocking and 
competitive ELISAs, a lower signal is associated with a positive sample of higher 
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concentration of antibody. The benefit for both these assays is an increase in specificity 
since both primary and secondary antibodies are targeting the same antigenic sites. In 
addition, the competitive ELISA can be used, in certain circumstances, to confirm that 
high affinity antibodies towards the antigen are present, such as neutralizing antibodies. 
The disadvantage with these assays is that the primary and conjugated antibodies may 
bind to different epitopes present on the antigen, in which case the conjugated antibodes 
are not truly blocking or competing with the primary antibodies. In addition, if overtime 
the antigenic sites of the pathogen evolve through mutation, the serum antibodies 
developed against them may not be recognized in the assay. Both of these disadvantages 
would result in a decrease in sensitivity. 
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ABSTRACT 
 The  A potential mechanism by which highly pathogenic avian influenza H5N1 
viruses could become established in humans would be through the infection of and 
adaptation in pigs. To detect the occurrence of such adaptation, monitoring of the pig 
populations in endemic H5N1 areas, potentially through serological screening, would be 
necessary. In the current study, we determined that the hemagglutination inhibition 
assays would have limited ability to detect antibodies against H5N1 developed in pigs, 
primarily because the use of multiple virus strains would be required. We developed 
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whole recombinant virus and recombinant hemagglutinin antigen enzyme-linked 
immunosorbent assays (ELISAs) for detection of antibody against multiple H5N1 strains 
and determined that, based on sensitivity, the recombinant hemagglutinin antigen-based 
ELISA outperformed the whole virus antigen ELISA assays for the virus strains used in 
this study. These results provide important information and considerations for the 
development of serological screening assays for highly pathogenic avian influenza H5N1 
viruses. 
INTRODUCTION 
 In 1997, a severe influenza-like illness was described in human patients in several 
countries in Southeast Asia. Diagnostic testing determined that the individuals had been 
infected with a highly pathogenic avian influenza (HPAI) virus from the H5N1 serotype1, 
2. Infection of humans by avian influenza viruses is uncommon at least in part because 
avian influenza viruses prefer α-2,3 sialic acid glycoprotein receptors, and these receptors 
in the human respiratory tract are primarily distributed deep within the lung 3. The 
distribution of α-2,3 sialic acid glycoprotein receptors in humans may contribute to the 
severe pneumonia caused by infection with HPAI H5N1 4. Contrarily, the lack of viral 
receptors in the upper respiratory tract may reduce susceptibility to infection by airborne 
avian virus and decrease the likelihood of viral transmission to another host 5. 
Nonetheless, direct interspecies transmission of avian influenza viruses to humans is 
possible and is postulated to have been responsible for the 1918 influenza pandemic 6. 
 The greatest concern with HPAI is the possibility of the virus adapting and 
establishing itself within the human population either through regular interspecies 
infection and horizontal transmission within the human population or through adaptation 
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in a secondary host, such as the pig. In contrast to human infection, pigs infected with 
HPAI H5N1 are asymptomatic to mildly symptomatic during infection, suggesting the 
virus’s impact on a swine host is minimal7-9. Diagnostically the lack of clinical symptom 
presentation in pigs could result in underreporting of HPAI H5N1 infection in pigs and 
could allow the virus to persist in a small number of pigs within a population facilitating 
adaptation. Evidence suggests the pig can serve as a "mixing vessel" supporting both 
human and avian influenza virus replication, attributed to the presence of both human α-
2,6 and avian α-2,3 sialic acid receptors in the upper respiratory tract 10. However, recent 
data indicate that the distribution of sialic acid receptors in the respiratory tract of pigs is 
similar to that in humans, suggesting that reassortment of virus genes is no more likely to 
occur in swine than in human or a few other mammalian hosts 11, 12.Sporadic instances of 
H5N1 HPAI influenza infection of pigs in southeast Asia have been reported8, 9. Also, a 
HPAI H5N1 virus was isolated from swine in Indonesia that expressed a preference for 
the human α-2,6 sialic acid receptor suggesting that adaptation had occurred 9. Because of 
the potential risk that HPAI H5N1 infection of pigs could pose to human health, 
development of screening methodologies that can identify the occurrence and prevalence 
of HPAI infection in swine populations should be a priority. 
 Additionally, the consequences of HPAI H5N1 establishing itself within the 
swine population could have detrimental effects within the swine industry. As stated 
earlier, H5N1 HPAI infection in pigs is commonly asymptomatic thus posing only a mild 
threat to swine health; however, these viruses are not fully adapted to a swine host and 
one could speculate that adaptation could increase infectivity and severity of disease. The 
consequences would also not be limited to direct effects from infection but also due to 
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indirect socioeconomic effects. As illustrated in 2009, simply referring to the virus as 
"swine influenza" resulted in false interpretations of the virus by the public and had 
negative effects towards pork sales and production 13. Because of the potential risk that 
HPAI H5N1 infection of pigs could pose to human health and the swine industry, 
development of screening methodologies that can identify the occurrence and prevalence 
of HPAI infection in swine populations should be a priority. 
 In this study, we evaluated the efficacy of hemagglutination inhibition assays for 
detection of antibodies in recombinant H5N1-vaccinated pigs. We sought to develop 
ELISA assays using either whole recombinant H5N1 viruses or recombinant HA antigen. 
We determined that assays using whole virus as antigen had limitations when detecting 
antibodies in swine serum samples. In addition, we concluded that a recombinant HA 
ELISA would more likely yield a successful method because of increased specificity. 
MATERIALS AND METHODS 
Cells. Madin-Darby canine kidney (MDCK; ATCC) cells were maintained in EMEM 
(Eagle's modified essential medium, Mediatech) completed with 10% FBS (Fetal bovine 
serum, Atlanta Biologicals) and penicillin/streptomycin (100 IU/ml, Mediatech). EMEM 
media containing 0.4% bovine serum albumin (BSA), penicillin/streptomycin (100 
UI/ml), and 1 µg/ µl TPCK-treated trypsin was used instead of the standard growth media 
to support virus infection.  
Viruses. The recombinant H5N1 (rH5N1) viruses used in this study were developed 
using an eight-plasmid influenza A reverse genetics system previously described in 
Hoffmann et al. and were graciously provided by Richard Webby (St. Jude Children's 
Research Hospital; Memphis, TN). Briefly, plasmids encoding the both the 
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hemagglutinin and neuraminidase genes from HPAI H5N1 A/Vietnam/1203/04(rVN04), 
A/Whopper Swan/Mongolia/244/05(rWS05), or A/Japanese White Eye/Hong 
Kong/1038/06 (rJWE06) were combined with plasmids expressing the remaining six 
genes from A/Puerto Rico/8/34 (PR8) and transfected into a coculture of MDCK and 
293T cells to rescue viruses. Additionally, the polybasic site located in H5 
hemagglutinins were replaced with a corresponding sequence from a lower pathogenic 
avian influenza (LPAI) H6N1 virus to render the viruses LPAI (described in  Hoffman et 
al.14). Both the removal of the polybasic site and the use of the six PR8 gene segments 
were used to attenuate the virus. The viruses were grown either in embryonated chicken 
eggs or in MDCK cells. 
Vaccine preparation. MDCK-propagated viral preparations of the three H5N1 
recombinant (rH5N1) viruses were concentrated and clarified using differential 
centrifugation for vaccine production. After a freeze-thaw of each preparation, the virus 
stocks were centrifuged at 10,000 x g at 4°C for 30 min to remove the cellular debris. The 
supernatants were collected for ultracentrifugation using a Ti 45 rotor (Beckman Coulter) 
at 30,000 rpm at 4°C for 1.5 h. The media was then discarded and the viral pellet was 
resuspended in 4 ml of phosphate buffered saline (PBS; 137 mM NaCl, 3 mM KCl, 8 
mM Na2HPO4 (pH 7.5)). The HA units (HAU)/ml were determine by incubating 50 µl of 
2-fold serial dilutions of the virus preps using PBS with 50 µl of 1% turkey red blood 
cells (RBC) in PBS. The concentrated virus solutions where placed in 100 mm dishes and 
then UV-inactivated for 3 min using a Stratalinker 2400 UV crosslinker (Stratagene). 
UV-inactivation of concentrated virus was confirmed to be replication deficient via 
immunocytochemistry TCID50 assay. Virus suspensions were diluted with PBS to a 
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concentration of 128 
HAU/ml, with the 
exception of the 
initial preparation of 
rWS06 that had a 
concentration of 96 
HAU/ml. The vaccine preparations also contained a final concentration of 20% v/v 
Emulsigen-D adjuvant (MVP Technologies).  
Production of hyperimmune swine serum. Five-week-old pigs seronegative for anti-
influenza antibody were used for this study, in compliance with the National Animal 
Disease Center Institutional Animal Care and Use Committee guidelines. For each 
rH5N1 vaccine, two pigs were vaccinated with a 2 ml dose and were given booster 
vaccinations at 14 and 33 days post initial vaccination (dpv). Serum samples were 
collected prior to vaccination and at 8, 14, 22, and 33 dpv to monitor antibody response 
to vaccination and for subsequent use in development and validation of ELISA assays. 
After 40 dpv, pigs were euthanized via intra-peritoneal injection for collection of 
hyperimmune serum. The hyperimmune serum was aliquoted into 50ml tubes and stored 
at -20 °C. Sera from pigs infected with endemic swine influenza viruses, one pig per 
virus, in a previous study were used for determination of the specificity of each ELISA 
(Table 1)15.  
Hemagglutination inhibition (HI) assay. HAU/ml titers for each virus were determined 
using 96-well U-bottom plates and incubating fifty microliters of two-fold serially diluted 
virus (1:2-1:2048) with fifty microliters of 1% turkey RBCs in PBS. Plates were mixed 
 Table 1.  Hemagglutination inhibition titers against homologous virus in 
serum from pigs inoculated with endemic non-H5 subtype viruses. 
(Leuwerke et al.) These sera were used to evaluate specificity of rH5N1 
ELISAs developed in this study.  
Isolate Name  Subtype  HI Titer 
A/Swine/Wisconsin/R33f/01  H1N2A  1280 
A/Swine/Iowa/40776/93  cH1N1  640 
A/Swine/Iowa/35233/99  tH1N1B  160 
A/Swine/Texas/4199-2/98  H3N2C1  1280 
A/Swine/Wisconsin/R7c/01  H3N2C3  640 
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with gentle tapping and were incubated for an hour at room temperature. HAU/ml titer 
was calculated as the reciprocal of the highest dilution agglutination occurred. Each assay 
was done in duplicate and confirmed with independent replicates. Serum samples were 
treated with receptor destroying enzyme (RDE) (100 µl of serum with 300 µl RDE 
solution; Lonza) and incubated overnight at 37°C. After RDE treatment, serum was 
brought to a final 1:10 dilution by the addition of 600 µl of physiological saline (0.85% 
w/v NaCl solution). Fifty microliters of diluted serum was added to each well the first 
row of 96-well U-bottom plates and 2-fold serial dilutions (1:10-1:2560) prepared. Each 
sample and dilution was performed in duplicate. An equivalent volume of virus at 8 
HAU/ml concentration was added to each well, mixed by tapping the plates gently, and 
incubated at room temperature for 1 h. Fifty microliters of 1% turkey RBCs in PBS was 
added, mixed by tapping, and incubated for another hour at room temperature. HI titers 
were determined as the reciprocal of the highest dilution inhibiting agglutination. 
Reported HI titers are the geometric mean of three individual HI assay replicates. 
Optimization of Whole Virus and Recombinant ELISA assays. Using the ELISA 
protocol described below, checkerboards comparing combinations of antigen dilutions (2-
256 HAU/ml rH5N1 virus or recombinant A/Vietnam/1203/05 HA protein [Protein 
Science Corporation]) and homologous serum sample dilutions (1:10-1:20480) were 
utilized to optimize assay  conditions. Assays using these conditions were then performed 
to optimize the conjugate antibody dilution (1:500-1:64000). For both assays, the final 
conditions were determined by determining the highest average absorbance (OD) from 
two independent assays. Similar checkerboards using negative (day 0) serum samples 
were performed at the same time to optimize conditions (Table 2). 
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 ELISA assay protocol. Concentration of antigen, serum sample, and conjugate antibody 
described in ELISA optimization section were tested and concentrations for final ELISA 
assays were established (Table 4). Allantoic fluids from embryonated chicken eggs 
infected with rVN04, rWS05, or rJWE06 were centrifuged at 10,000 x g at 4°C for 10 
min to remove cellular debris and the resulting virus suspensions were used in the ELISA 
assay. Immulon 2HB plates (Thermo Scientific) were coated with 100 µl of diluted 
rH5N1 virus or rHA resuspended in PBS and incubated overnight at 37 °C. Plates were 
washed three times using PBS with 0.05% Tween 20 (PBS-T) and tapped onto paper 
towels between washes to remove residual liquid. Serum samples were then diluted with 
ELISA diluent (PBS with 0.5% gelatin, 0.15% Tween 20, and 4% goat serum), and 100 
µl of diluted sample were added to a well and incubated at room temp for 1.5 h. After the 
plates were washed three times with PBS-T, 100 µl of goat anti-swine HRP-conjugated 
antibody (KPL) diluted 1:500 in ELISA diluent was added to each well and incubated for 
1 h at room temperature. Again, the plates were washed three times with PBS-T prior to 
the addition of 100 µl of substrate (10 mg o-phenylenediamine in 20 ml of .05M 
phosphate citrate buffer, containing 0.03% sodium perborate). The plates were incubated 
until color development was complete (approximately 1 min) and stopped with 1 N 
sulfuric acid. Using a Multiskan plate reader with Ascent software (Thermo), sample 
absorbance (OD) was determined at a wavelength of 492nm.  
Sample Analysis: Statistical analysis of ELISA data was performed with the assistance 
of Dr. Chong Wang. Data from two independent ELISA assay replicates were combined 
and analyzed using receiver operating characteristics (ROC) statistical methods to 
determine assay cut-off values for calculation of specificity and sensitivity for each assay. 
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Criteria for selecting cut-off values included 
eliminating detection of non-H5N1 samples 
(non-H5N1 serum sample sensitivity= 0) 
and maximizing both the specificity and 
sensitivity for each assay. 
RESULTS 
Antibody production in vaccinated pigs. 
To monitor antibody production in the 
vaccinated pigs, homologous HI titers were 
determined for serum samples collected 0, 8, 22, and 40 dpv. (Table 2). The HI titers 
indicated that by day eight all six pigs were seropositive (HI titer ≥40) for antibodies 
against the rH5N1 viruses. Therefore, all of the post-vaccination sequential serum 
samples were used to determine the sensitivity of the ELISA assays, providing a wide 
range of antibody titers for the assays. 
H5N1 are antigenically variant by hemagglutination inhibition. To determine the 
relative HI antibody cross-reactivity between the rH5N1 viruses and heterologous versus 
homologous H5 hyperimmune serum, we performed heterospecific HI assays using the 
serum samples collected at 40 dpv. The HI titers differed substantially depending on the 
viral strain used for antibody detection (Table 3). HI titers measured by rVN04 virus in 
heterologous serum samples from rJWE06 vaccinated pigs differed 16-fold from HI titers 
measured with homologous virus. Similar results were also seen when using the rWS05 
for detection of antibody in serum from rVN04- and rJWE06-vaccinated pigs; HI titers 
were 6- and 8-fold lower, respectively, than with homologous virus. However, when the 
 Table 2. Hemagglutination inhibition assay 
titers of sequential serum samples from rH5N1-
vaccinated pigs demonstrating development of 
antibody as measured by homologous virus.  
 HI Titer 
Pig* 8 dpv 22 dpv 40 dpv 
VN-1 80 160 508 
VN-2 80 160 508 
WS-1 160 320 1280 
WS-2 160 320 806 
JWE-1 80 320 640 
JWE-2 80 640 905 
 
*Two pigs each were vaccinated with rVN04 (VN), rWS05 
(WS), or rJWE06 
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 Table 4. Optimized ELISA protocol conditions determined from 
checkerboard analysis for the whole virus and recombinant hemagglutinin 
ELISA assays. 
 
 
rVN04 rWS05 rJWE06 rHA 
Sample Dilution 1:160 1:160 1:320 1:80 
Antigen concentration 64 HAU 64 HAU 256 HAU 4 µg/ml 
Conjugate dilution 1:500 1:500 1:500 1:500 
 
rJWE06 virus was used for detection of 
antibody in serum from pigs vaccinated with 
rVN04 and rWS05, the HI titers of the 
heterologous serum samples were similar to 
those measured with homologous virus 
counterparts (within a 2-fold difference). In 
summary, these results illustrate antigenic 
variation between H5N1 viruses, as detected 
by HI test, which could hinder use of this test 
in swine for diagnostic purposes. The results are consistent with those of previous studies 
using serum from pigs infected with endemic swine IAV viruses in which similar 
differences between homologous and heterologous HI titers were evident 15. 
Optimization of ELISA parameters. ELISA assays were optimized for sample dilution, 
antigen concentration, and conjugate antibody dilution as described (Table 4). The 
sample dilution and antigen concentration for both rVN04 and rWS05 ELISA assays with 
the optimal sera dilution being 1:160 and the antigen concentration being 64 HAU. In 
contrast to these two assays, the sera dilution for rJWE06 ELISA appeared to be best 
around 1:320 and the maximum virus concentration (256 HAU) was necessary for this 
assay. The rHA 
ELISA OD values 
appeared to be 
highest at a sera 
dilution of 1:80 and 
 Table 3. Heterospecific hemagglutination 
inhibition assay titers comparing antibodies 
titers using different rH5N1 viruses in the 
assays. 
 Virus 
Pig rVN04 rWS05 rJWE06 
VN-1 508 80 320 
VN-2 508 40 320 
WS-1 320 1280 1280 
WS-2 160 806 640 
JWE-1 40 80 640 
JWE-2 40 80 905 
 
Boxes indicate homologous HI assay titers. 
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4µg/ml of rHA protein. Due to cost, 4µg/ml was set as the maximum allowable 
concentration, but 2µg/ml would most likely would have been improved the assay 
because the difference in OD values was not too substantial. For all four assays 
increasing the concentration of the HRP conjugated antibody directly resulted in an 
increase of OD values, so the minimal dilution (1:500) was used. 
Whole virus ELISA specificity 
for antibody against H5 viruses 
is limited. Using the optimized 
conditions, each ELISA was 
analyzed statistically using ROC 
for determination of the cut-off 
values and calculation of the 
sensitivity and specificity for each assay (Table 5; ROC analysis with raw OD values 
listed as Sup. Table 1-4). To minimize the potential for false positive results, cut-off 
values were selected for each assay to eliminate detection of non-H5N1 serum samples. 
As a result, all three whole virus ELISA assays had specificities of a hundred percent 
(Table 5). For theses assays, serum samples collected between 8 to 40 dpv, regardless of 
the virus used for vaccination, were considered positive for analysis. Based on these 
parameters, the rWS05 and rJWE06 ELISA assays appeared to work similarly with 
calculated low sensitivities of 37% and 38%, respectively. The rVN04 ELISA out 
performed both of the other whole virus assays with a sensitivity around 48%. 
Nevertheless, these results indicate that the majority of positive samples were undetected 
with this assay. 
 Table 5. Specificity and sensitivity for each ELISA 
determined through ROC analysis and calculation of cut-off 
values. 
Assay Cut-off* Specificity Sensitivity  
rVN04 1.357 100% 48% 
rWS05 0.93 100% 37% 
rJWE06 0.647 100% 38% 
rHA 0.503 100% 60% 
 
*Only cut-off values with non-H5N1 sensitivity equaling zero were 
considered (Sup. Table 1-4). 
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Recombinant HA ELISA can detect H5N1 antibodies efficiently. To determine if the 
low specificity for antibody against H5 viruses versus non-H5 viruses, and the 
consequent low sensitivity for anti-H5 antibody that resulted from the cut-off value 
established from these data, could be due to cross-reactivity between antibodies in the 
sera and other conserved proteins in the various viruses, we coated plates with a 
recombinant hemagglutinin (rHA) protein from A/Vietnam/1203/04 and performed the 
ELISA using a similar protocol. Similar to the whole virus assays, the rHA ELISA assay 
had a specificity of 100% because of cut-off value selection. However, use of the 
recombinant protein increased the sensitivity to 60%, which is significantly higher than 
the whole virus assays and allowed for detection of a majority of the H5N1 serum 
samples. These results suggest rHA ELISA assays may be preferable to recombinant 
whole virus assays for increased sensitivity by decreasing the specificity to non-H5N1 
serum samples.  
DISCUSSION 
 To detect possible interspecies transmission of HPAI H5N1 into pigs, or to 
monitor prevalence of such infection in swine populations should such an event occur, 
would require development of inexpensive and effective, i.e. specific and sensitive, 
serologic assays to detect H5N1 virus specific antibodies in swine serum. Until recent 
years, the hemagglutination inhibition assay for detection of subtype specific antibody 
against influenza viruses was the standard test for serologic detection of influenza virus 
infection in swine. Using the three rH5N1 viruses described in this study, we performed 
HI assays and compared their ability to detect antibody in heterologous rH5N1 serum 
samples. Our results indicate that detection of antibodies against rH5N1 via 
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hemagglutination inhibition is strain specific and can result in a multiple-fold difference 
in HI titer, as seen in the rVN04 and rWS05 HI assays (Table 3). This difference in 
antibody detection may be partially due to the rapid evolution of the hemagglutinin 
antigenic sites in H5N1 HPAI resulting in either decreasing the affinity of the antibody 
for the hemagglutinin or  targeting of non-HI epitopes 16. However, when rJWE06 was 
used in the HI assay, the antibody titers measured by this virus in heterologous sera were 
similar to those measured with homologous virus. In summary, our results indicate that 
the level of detection of antibody against H5N1 in swine serum using HI assays is 
dependent on the viral strains used for detection and would require use of multiple strains 
in order to accurately detect and calculate H5N1 antibody titers.  
 With detection of heterologous H5N1 antibodies by HI assays being limited by 
antigenic variation between viruses, we sought to develop another method for serological 
detection of H5N1. We developed indirect ELISA assays using plates coated with either 
whole virus or recombinant hemagglutinin antigens to examine their potential for 
serological detection. We determined that whole virus antigen ELISAs had significant 
difficulties differentiating between antibodies developed against H5N1 viruses and 
endemic swine influenza viruses, resulting in the selection of cut-off values by ROC that 
defined positive for only a minority of the rH5N1 serum samples. However, the rHA 
antigen ELISA had a greater ability to differentiate between anti-H5 and anti non-H5 
antibody, allowing selection of a higher cut-off value with increased potential for use in 
the field. The increased sensitivity observed when using rHA ELISA assay is likely the 
result of decreased cross-reactivity with non-subtype specific antibodies to epitopes that 
are conserved between the viral strains. Keeping cross-detection at a minimum was a 
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priority since many to most pigs have antibody against non-H5N1 viruses, and false 
positive results could lead to decisions with serious negative financial consequences. 
Therefore, all the results from the ELISA assays reported here use cut-off values in which 
non-H5N1 sensitivity was 0.  
 The rHA indirect ELISA format may be a useful tool for screening H5N1 
antibody in swine population. Unfortunately, all four ELISA assays were unable to detect 
all of the HI-positive serum samples, and only the rHA assay was able to detect a 
majority (60%) of the samples. This suggests that the HI assays were more sensitive than 
the ELISA assays, especially early in infection, or that there may be a minimal detection 
limit for hemagglutinating or other antibodies with any of the ELISA assays. Decreasing 
the cross-reactivity is necessary to increase the sensitivity by allowing lower cut-off 
values. This may be achieved by including non-H5N1 sera during concentration 
optimization to determine conditions in which detection of non-H5N1 sera is minimal. In 
addition, similar to the HI assays the ELISA assays may have difficulties detecting 
heterospecifc antibodies, though this was not apparent in the ELISA data (Sup. Table 1-
4). This could be potentially overcome by using multiple rHA proteins in the ELISA 
assay. Future work may be necessary in order to determine the minimal HI titer 
detectable by each assay and the effects that heterosubtypic antibodies have on 
specificity.  
 Given the zoonotic potential of influenza viruses, monitoring the introduction of 
potentially high-risk viruses into our production animals should be a priority. In this 
study, we illustrated that H5N1 serological assays, based upon whole virus antigen, may 
have a number of inherent limitations in their ability to detect H5N1 specific antibody. 
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However, assays based on recombinant proteins, may allow for an increased level of non-
H5 specificity that is cross-reactive with other H5N1 species, allowing for detection of a 
broader range of H5 viruses. This work lays the groundwork and considerations for 
development of serological detection of antibodies against H5N1 in pigs. 
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Sup. Table 1. ROC calculated cutoff values, specificities, and sensitivities for rVN04 ELISA assay 
Replicate Pig 
Time 
(dpv) 
Cut-
off 
H5N1 
Spec. 
H5N1 
Sens. 
non-
H5N1 
Sens. Replicate Pig 
Time 
(dpv) 
Cut-
off 
H5N1 
Spec. 
H5N1 
Sens. 
non-
H5N1 
Sens. 
1 JWE-1 0 0.154 0.0% 100.0% 100.0% 2 WS-2 33 1.258 100.0% 50.0% 10.0% 
1 VN-1 8 0.177 8.3% 100.0% 100.0% 1 H1N2A na 1.288 100.0% 48.3% 10.0% 
2 VN-1 0 0.216 8.3% 98.3% 100.0% 2 JWE-1 22 1.357 100.0% 48.3% 0.0% 
1 VN-1 0 0.223 16.7% 98.3% 100.0% 1 JWE-1 33 1.378 100.0% 46.7% 0.0% 
1 WS-1 0 0.245 25.0% 98.3% 100.0% 2 JWE-1 33 1.381 100.0% 45.0% 0.0% 
1 WS-1 8 0.247 33.3% 98.3% 100.0% 2 WS-1 33 1.382 100.0% 43.3% 0.0% 
2 WS-1 0 0.247 33.3% 96.7% 100.0% 1 JWE-1 22 1.395 100.0% 41.7% 0.0% 
1 WS-2 8 0.266 41.7% 96.7% 100.0% 2 JWE-2 22 1.453 100.0% 40.0% 0.0% 
1 VN-2 8 0.267 41.7% 95.0% 100.0% 2 JWE-2 33 1.472 100.0% 38.3% 0.0% 
1 VN-2 0 0.272 41.7% 93.3% 100.0% 2 JWE-1 40 1.54 100.0% 36.7% 0.0% 
2 WS-2 0 0.284 50.0% 93.3% 100.0% 1 JWE-2 33 1.549 100.0% 35.0% 0.0% 
2 JWE-2 0 0.31 58.3% 93.3% 100.0% 1 JWE-1 40 1.576 100.0% 33.3% 0.0% 
1 WS-2 0 0.312 66.7% 93.3% 100.0% 1 JWE-2 22 1.607 100.0% 31.7% 0.0% 
1 JWE-2 0 0.316 75.0% 93.3% 100.0% 2 VN-2 33 1.641 100.0% 30.0% 0.0% 
2 JWE-1 0 0.318 83.3% 93.3% 100.0% 1 VN-2 22 1.647 100.0% 28.3% 0.0% 
1 WS-2 14 0.325 91.7% 93.3% 100.0% 2 WS-2 40 1.671 100.0% 26.7% 0.0% 
1 JWE-1 14 0.339 91.7% 91.7% 100.0% 1 VN-2 33 1.672 100.0% 25.0% 0.0% 
2 WS-1 8 0.344 91.7% 90.0% 100.0% 2 VN-2 22 1.682 100.0% 23.3% 0.0% 
1 JWE-1 8 0.4 91.7% 88.3% 100.0% 2 VN-1 33 1.704 100.0% 21.7% 0.0% 
2 WS-2 14 0.418 91.7% 86.7% 100.0% 1 WS-2 40 1.738 100.0% 20.0% 0.0% 
1 WS-1 14 0.423 91.7% 85.0% 100.0% 2 VN-1 22 1.754 100.0% 18.3% 0.0% 
2 VN-2 8 0.435 91.7% 83.3% 100.0% 1 VN-1 33 1.755 100.0% 16.7% 0.0% 
1 VN-1 14 0.452 91.7% 81.7% 100.0% 1 VN-1 22 1.806 100.0% 15.0% 0.0% 
2 WS-2 8 0.506 91.7% 80.0% 100.0% 2 WS-1 40 1.839 100.0% 13.3% 0.0% 
2 JWE-1 8 0.509 91.7% 78.3% 100.0% 1 WS-1 40 1.854 100.0% 11.7% 0.0% 
2 VN-1 8 0.522 91.7% 76.7% 100.0% 2 VN-1 40 1.863 100.0% 10.0% 0.0% 
2 VN-2 0 0.523 91.7% 75.0% 100.0% 1 JWE-2 40 1.872 100.0% 8.3% 0.0% 
2 VN-1 14 0.553 100.0% 75.0% 100.0% 2 VN-2 40 1.872 100.0% 6.7% 0.0% 
1 JWE-2 8 0.575 100.0% 73.3% 100.0% 1 VN-2 40 1.874 100.0% 5.0% 0.0% 
2 WS-1 14 0.595 100.0% 71.7% 100.0% 2 JWE-2 40 1.877 100.0% 3.3% 0.0% 
2 JWE-1 14 0.624 100.0% 70.0% 100.0% 1 VN-1 40 1.892 100.0% 1.7% 0.0% 
1 VN-2 14 0.674 100.0% 68.3% 100.0%        
2 JWE-2 8 0.738 100.0% 66.7% 100.0%        
1 tH1N1B na 0.756 100.0% 65.0% 100.0%        
2 tH1N1B na 0.764 100.0% 65.0% 90.0%        
1 JWE-2 14 0.795 100.0% 65.0% 80.0%        
2 VN-2 14 0.889 100.0% 63.3% 80.0%        
2 JWE-2 14 0.98 100.0% 61.7% 80.0%        
2 WS-2 22 1.028 100.0% 60.0% 80.0%        
2 cH1N1 na 1.045 100.0% 58.3% 80.0%        
1 WS-2 33 1.048 100.0% 58.3% 70.0%        
1 WS-2 22 1.051 100.0% 56.7% 70.0%        
1 H3N2C1 na 1.054 100.0% 55.0% 70.0%        
2 H3N2C3 na 1.071 100.0% 55.0% 60.0%        
1 H3N2C3 na 1.079 100.0% 55.0% 50.0%        
1 WS-1 22 1.091 100.0% 55.0% 40.0%        
1 cH1N1 na 1.115 100.0% 53.3% 40.0%        
2 H1N2A na 1.171 100.0% 53.3% 30.0%        
1 WS-1 33 1.196 100.0% 53.3% 20.0%        
2 H3N2C1 na 1.208 100.0% 51.7% 20.0%        
2 WS-1 22 1.214 100.0% 51.7% 10.0%        
 
Reported cutoff value, specificity, and sensitivity are shaded grey  
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Sup. Table 2. ROC calculated cutoff values, specificities, and sensitivities for rWS05 ELISA assay 
Replicate Pig 
Time 
(dpv) 
Cut-
off 
H5N1 
Spec. 
H5N1 
Sens. 
Non-
H5N1 
Sens. Replicate Pig 
Time 
(dpv) 
Cut-
off 
H5N1 
Spec. 
H5N1 
Sens. 
Non-
H5N1 
Sens. 
1 JWE-1 0 0.164 0.0% 100.0% 100.0% 1 WS-1 22 0.835 100.0% 50.0% 10.0% 
1 VN-1 0 0.166 8.3% 100.0% 100.0% 2 WS-2 22 0.837 100.0% 48.3% 10.0% 
2 JWE-1 0 0.176 16.7% 100.0% 100.0% 1 VN-1 33 0.848 100.0% 46.7% 10.0% 
1 WS-2 8 0.217 25.0% 100.0% 100.0% 2 VN-1 33 0.852 100.0% 45.0% 10.0% 
1 WS-1 0 0.238 25.0% 98.3% 100.0% 2 JWE-1 22 0.877 100.0% 43.3% 10.0% 
2 JWE-2 0 0.248 33.3% 98.3% 100.0% 1 WS-2 22 0.889 100.0% 41.7% 10.0% 
2 JWE-1 8 0.249 41.7% 98.3% 100.0% 2 JWE-2 33 0.917 100.0% 40.0% 10.0% 
1 JWE-2 0 0.253 41.7% 96.7% 100.0% 1 VN-1 22 0.922 100.0% 38.3% 10.0% 
1 VN-1 14 0.256 50.0% 96.7% 100.0% 1 H1N2A na 0.925 100.0% 36.7% 10.0% 
1 JWE-1 8 0.262 50.0% 95.0% 100.0% 1 JWE-1 33 0.93 100.0% 36.7% 0.0% 
1 WS-2 0 0.271 50.0% 93.3% 100.0% 1 JWE-1 22 0.936 100.0% 35.0% 0.0% 
1 WS-1 8 0.273 58.3% 93.3% 100.0% 2 JWE-2 22 0.951 100.0% 33.3% 0.0% 
1 VN-2 8 0.281 58.3% 91.7% 100.0% 2 JWE-1 33 0.964 100.0% 31.7% 0.0% 
2 VN-1 0 0.297 58.3% 90.0% 100.0% 1 WS-2 33 1.003 100.0% 30.0% 0.0% 
1 VN-2 14 0.301 66.7% 90.0% 100.0% 1 WS-1 33 1.041 100.0% 28.3% 0.0% 
1 VN-1 8 0.305 66.7% 88.3% 100.0% 2 JWE-1 40 1.041 100.0% 26.7% 0.0% 
1 JWE-1 14 0.305 66.7% 86.7% 100.0% 2 WS-1 33 1.101 100.0% 25.0% 0.0% 
2 WS-1 8 0.315 66.7% 85.0% 100.0% 2 VN-1 40 1.116 100.0% 23.3% 0.0% 
1 VN-2 0 0.319 66.7% 83.3% 100.0% 2 WS-2 33 1.124 100.0% 21.7% 0.0% 
2 VN-1 14 0.323 75.0% 83.3% 100.0% 1 JWE-2 22 1.135 100.0% 20.0% 0.0% 
2 WS-2 0 0.343 75.0% 81.7% 100.0% 2 VN-2 40 1.171 100.0% 18.3% 0.0% 
2 VN-1 8 0.352 83.3% 81.7% 100.0% 1 JWE-2 33 1.213 100.0% 16.7% 0.0% 
2 WS-2 14 0.354 83.3% 80.0% 100.0% 1 VN-2 40 1.239 100.0% 15.0% 0.0% 
2 WS-1 0 0.364 83.3% 78.3% 100.0% 2 WS-1 40 1.273 100.0% 13.3% 0.0% 
1 JWE-2 8 0.372 91.7% 78.3% 100.0% 1 JWE-1 40 1.33 100.0% 11.7% 0.0% 
1 WS-2 14 0.388 91.7% 76.7% 100.0% 1 VN-1 40 1.432 100.0% 10.0% 0.0% 
2 VN-2 8 0.412 91.7% 75.0% 100.0% 1 JWE-2 40 1.561 100.0% 8.3% 0.0% 
1 WS-1 14 0.417 91.7% 73.3% 100.0% 1 WS-2 40 1.568 100.0% 6.7% 0.0% 
1 JWE-2 14 0.427 91.7% 71.7% 100.0% 1 WS-1 40 1.643 100.0% 5.0% 0.0% 
2 WS-1 14 0.476 91.7% 70.0% 100.0% 2 WS-2 40 1.675 100.0% 3.3% 0.0% 
2 JWE-1 14 0.523 91.7% 68.3% 100.0% 2 JWE-2 40 1.712 100.0% 1.7% 0.0% 
2 WS-2 8 0.546 91.7% 66.7% 100.0%        
2 tH1N1B na 0.559 91.7% 65.0% 100.0%        
2 VN-2 0 0.563 91.7% 65.0% 90.0%        
1 tH1N1B na 0.595 100.0% 65.0% 90.0%        
2 JWE-2 8 0.611 100.0% 65.0% 80.0%        
2 H3N2C1 na 0.656 100.0% 63.3% 80.0%        
2 H3N2C3 na 0.711 100.0% 63.3% 70.0%        
1 H3N2C3 na 0.713 100.0% 63.3% 60.0%        
1 VN-2 22 0.725 100.0% 63.3% 50.0%        
2 VN-2 33 0.737 100.0% 61.7% 50.0%        
2 VN-2 22 0.74 100.0% 60.0% 50.0%        
2 cH1N1 na 0.744 100.0% 58.3% 50.0%        
2 VN-2 14 0.751 100.0% 58.3% 40.0%        
2 WS-1 22 0.756 100.0% 56.7% 40.0%        
1 VN-2 33 0.76 100.0% 55.0% 40.0%        
2 H1N2A na 0.771 100.0% 53.3% 40.0%        
1 H3N2C1 na 0.801 100.0% 53.3% 30.0%        
1 cH1N1 na 0.812 100.0% 53.3% 20.0%        
2 VN-1 22 0.818 100.0% 53.3% 10.0%        
2 JWE-2 14 0.827 100.0% 51.7% 10.0%        
 
Reported cutoff value, specificity, and sensitivity are shaded grey  
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Sup. Table 3. ROC calculated cutoff values, specificities, and sensitivities for rJWE06 ELISA assay 
Replicate Pig 
Time 
(dpv) 
Cut-
off 
H5N1 
Spec. 
H5N1 
Sens. 
Non-
H5N1 
Sens. Replicate Pig 
Time 
(dpv) 
Cut-
off 
H5N1 
Spec. 
H5N1 
Sens. 
Non-
H5N1 
Sens. 
1 JWE-1 0 0.139 0.0% 100.0% 100.0% 2 VN-1 22 0.538 100.0% 45.0% 40.0% 
1 WS-1 8 0.146 8.3% 100.0% 100.0% 2 JWE-2 14 0.551 100.0% 43.3% 40.0% 
1 VN-2 8 0.149 8.3% 98.3% 100.0% 2 H3N2C1 na 0.559 100.0% 41.7% 40.0% 
1 WS-2 8 0.149 8.3% 96.7% 100.0% 1 VN-1 33 0.576 100.0% 41.7% 30.0% 
1 VN-2 14 0.158 8.3% 95.0% 100.0% 1 VN-1 22 0.596 100.0% 40.0% 30.0% 
1 JWE-1 8 0.163 8.3% 93.3% 100.0% 2 cH1N1 na 0.596 100.0% 38.3% 30.0% 
1 WS-1 0 0.165 8.3% 91.7% 100.0% 1 H1N2A na 0.601 100.0% 38.3% 20.0% 
1 WS-2 14 0.166 16.7% 91.7% 100.0% 2 H1N2A na 0.623 100.0% 38.3% 10.0% 
1 VN-1 0 0.17 16.7% 90.0% 100.0% 2 WS-1 33 0.647 100.0% 38.3% 0.0% 
1 VN-2 0 0.181 25.0% 90.0% 100.0% 1 JWE-1 22 0.657 100.0% 36.7% 0.0% 
1 VN-1 8 0.205 33.3% 90.0% 100.0% 2 JWE-1 33 0.723 100.0% 35.0% 0.0% 
1 WS-1 14 0.206 33.3% 88.3% 100.0% 1 JWE-1 33 0.733 100.0% 33.3% 0.0% 
1 VN-1 14 0.207 33.3% 86.7% 100.0% 2 JWE-1 22 0.736 100.0% 31.7% 0.0% 
2 WS-2 14 0.209 33.3% 85.0% 100.0% 2 WS-2 33 0.808 100.0% 30.0% 0.0% 
1 JWE-1 14 0.214 33.3% 83.3% 100.0% 2 JWE-2 33 0.841 100.0% 28.3% 0.0% 
2 JWE-1 0 0.22 33.3% 81.7% 100.0% 2 VN-1 8 0.847 100.0% 26.7% 0.0% 
1 WS-2 0 0.227 41.7% 81.7% 100.0% 1 VN-2 40 0.866 100.0% 25.0% 0.0% 
1 JWE-2 8 0.231 50.0% 81.7% 100.0% 2 VN-2 40 0.867 100.0% 23.3% 0.0% 
2 WS-1 8 0.246 50.0% 80.0% 100.0% 1 JWE-1 40 0.887 100.0% 21.7% 0.0% 
2 VN-1 0 0.251 50.0% 78.3% 100.0% 2 JWE-1 40 0.914 100.0% 20.0% 0.0% 
2 WS-1 0 0.255 58.3% 78.3% 100.0% 1 JWE-2 22 0.92 100.0% 18.3% 0.0% 
1 JWE-2 14 0.257 66.7% 78.3% 100.0% 1 WS-2 40 0.928 100.0% 16.7% 0.0% 
2 JWE-1 8 0.266 66.7% 76.7% 100.0% 1 JWE-2 33 0.958 100.0% 15.0% 0.0% 
1 JWE-2 0 0.27 66.7% 75.0% 100.0% 2 VN-1 40 0.979 100.0% 13.3% 0.0% 
2 VN-2 8 0.283 75.0% 75.0% 100.0% 2 JWE-2 22 1.008 100.0% 11.7% 0.0% 
2 WS-2 0 0.294 75.0% 73.3% 100.0% 1 VN-1 40 1.097 100.0% 10.0% 0.0% 
2 VN-1 14 0.304 83.3% 73.3% 100.0% 2 WS-1 40 1.165 100.0% 8.3% 0.0% 
2 WS-1 14 0.306 83.3% 71.7% 100.0% 1 JWE-2 40 1.24 100.0% 6.7% 0.0% 
2 JWE-2 0 0.344 83.3% 70.0% 100.0% 1 WS-1 40 1.241 100.0% 5.0% 0.0% 
1 tH1N1B na 0.351 91.7% 70.0% 100.0% 2 WS-2 40 1.406 100.0% 3.3% 0.0% 
1 WS-2 33 0.362 91.7% 70.0% 90.0% 2 JWE-2 40 1.662 100.0% 1.7% 0.0% 
2 tH1N1B na 0.387 91.7% 68.3% 90.0%        
2 WS-2 8 0.388 91.7% 68.3% 80.0%        
2 VN-2 22 0.399 91.7% 66.7% 80.0%        
2 VN-2 0 0.404 91.7% 65.0% 80.0%        
2 JWE-1 14 0.415 100.0% 65.0% 80.0%        
1 WS-2 22 0.42 100.0% 63.3% 80.0%        
2 JWE-2 8 0.429 100.0% 61.7% 80.0%        
1 VN-2 22 0.435 100.0% 60.0% 80.0%        
2 WS-2 22 0.435 100.0% 58.3% 80.0%        
2 VN-2 33 0.44 100.0% 56.7% 80.0%        
2 WS-1 22 0.441 100.0% 55.0% 80.0%        
1 WS-1 33 0.449 100.0% 53.3% 80.0%        
2 VN-2 14 0.457 100.0% 51.7% 80.0%        
2 H3N2C3 na 0.475 100.0% 50.0% 80.0%        
1 H3N2C3 na 0.478 100.0% 50.0% 70.0%        
1 VN-2 33 0.483 100.0% 50.0% 60.0%        
2 VN-1 33 0.493 100.0% 48.3% 60.0%        
1 H3N2C1 na 0.517 100.0% 46.7% 60.0%        
1 cH1N1 na 0.533 100.0% 46.7% 50.0%        
1 WS-1 22 0.537 100.0% 46.7% 40.0%        
 
Reported cutoff value, specificity, and sensitivity are shaded grey  
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Sup. Table 4. ROC calculated cutoff values, specificities, and sensitivities for rHA ELISA assay 
Replicate Pig 
Time 
(dpv) 
Cut-
off 
H5N1 
Spec. 
H5N1 
Sens. 
non-
H5N1 
Sens. Replicate Pig 
Time 
(dpv) Cut-off 
H5N1 
Spec. 
H5N1 
Sens. 
non-
H5N1 
Sens. 
2 WS-2 0 0.106 0.0% 100.0% 100.0% 2 WS-2 33 0.729 100.0% 51.7% 0.0% 
2 VN-1 0 0.113 8.3% 100.0% 100.0% 2 WS-1 33 0.787 100.0% 50.0% 0.0% 
2 H3N2C1 na 0.114 16.7% 100.0% 100.0% 1 JWE-1 33 0.833 100.0% 48.3% 0.0% 
1 VN-1 0 0.125 16.7% 100.0% 90.0% 2 VN-2 14 0.874 100.0% 46.7% 0.0% 
1 WS-2 8 0.137 25.0% 100.0% 90.0% 2 VN-1 14 0.931 100.0% 45.0% 0.0% 
1 H3N2C1 na 0.143 25.0% 98.3% 90.0% 1 JWE-2 22 0.932 100.0% 43.3% 0.0% 
1 VN-1 8 0.146 25.0% 98.3% 80.0% 2 JWE-1 33 0.934 100.0% 41.7% 0.0% 
1 WS-2 14 0.149 25.0% 96.7% 80.0% 2 JWE-1 22 1.04 100.0% 40.0% 0.0% 
2 WS-2 8 0.161 25.0% 95.0% 80.0% 1 JWE-2 33 1.061 100.0% 38.3% 0.0% 
2 H3N2C3 na 0.166 25.0% 93.3% 80.0% 2 JWE-1 40 1.081 100.0% 36.7% 0.0% 
1 WS-2 0 0.173 25.0% 93.3% 70.0% 1 JWE-1 40 1.092 100.0% 35.0% 0.0% 
1 VN-2 8 0.179 33.3% 93.3% 70.0% 2 JWE-2 33 1.164 100.0% 33.3% 0.0% 
1 H3N2C3 na 0.189 33.3% 91.7% 70.0% 1 WS-2 40 1.206 100.0% 31.7% 0.0% 
2 VN-1 8 0.189 33.3% 91.7% 60.0% 2 JWE-2 22 1.216 100.0% 30.0% 0.0% 
2 WS-2 14 0.207 33.3% 90.0% 60.0% 2 WS-2 40 1.319 100.0% 28.3% 0.0% 
1 VN-2 0 0.208 33.3% 88.3% 60.0% 2 JWE-2 40 1.321 100.0% 26.7% 0.0% 
2 VN-2 0 0.226 41.7% 88.3% 60.0% 2 WS-1 40 1.399 100.0% 25.0% 0.0% 
2 JWE-2 0 0.232 50.0% 88.3% 60.0% 2 VN-2 33 1.475 100.0% 23.3% 0.0% 
1 tH1N1B na 0.24 58.3% 88.3% 60.0% 2 VN-2 40 1.48 100.0% 21.7% 0.0% 
1 JWE-1 14 0.253 58.3% 88.3% 50.0% 2 VN-1 40 1.542 100.0% 20.0% 0.0% 
1 JWE-2 0 0.255 58.3% 86.7% 50.0% 1 WS-1 40 1.562 100.0% 18.3% 0.0% 
2 JWE-1 14 0.258 66.7% 86.7% 50.0% 2 VN-2 22 1.576 100.0% 16.7% 0.0% 
2 tH1N1B na 0.263 66.7% 85.0% 50.0% 2 VN-1 33 1.588 100.0% 15.0% 0.0% 
2 VN-2 8 0.269 66.7% 85.0% 40.0% 2 VN-1 22 1.67 100.0% 13.3% 0.0% 
1 JWE-2 14 0.27 66.7% 83.3% 40.0% 1 JWE-2 40 1.757 100.0% 11.7% 0.0% 
2 WS-1 8 0.275 66.7% 81.7% 40.0% 1 VN-2 33 1.788 100.0% 10.0% 0.0% 
1 JWE-2 8 0.277 66.7% 80.0% 40.0% 1 VN-2 22 1.83 100.0% 8.3% 0.0% 
2 JWE-1 0 0.277 66.7% 78.3% 40.0% 1 VN-1 40 2.072 100.0% 6.7% 0.0% 
1 WS-1 8 0.285 75.0% 78.3% 40.0% 1 VN-1 33 2.082 100.0% 5.0% 0.0% 
2 JWE-1 8 0.296 75.0% 76.7% 40.0% 1 VN-1 22 2.127 100.0% 3.3% 0.0% 
2 JWE-2 8 0.296 75.0% 75.0% 40.0% 1 VN-2 40 2.131 100.0% 1.7% 0.0% 
1 WS-1 14 0.308 75.0% 73.3% 40.0%        
2 WS-1 0 0.311 75.0% 71.7% 40.0%        
1 JWE-1 0 0.318 83.3% 71.7% 40.0%        
1 JWE-1 8 0.324 91.7% 71.7% 40.0%        
2 WS-1 14 0.339 91.7% 70.0% 40.0%        
1 WS-1 0 0.351 91.7% 68.3% 40.0%        
1 WS-2 22 0.36 100.0% 68.3% 40.0%        
1 WS-1 22 0.366 100.0% 66.7% 40.0%        
1 cH1N1 na 0.381 100.0% 65.0% 40.0%        
1 H1N2A na 0.394 100.0% 65.0% 30.0%        
1 VN-1 14 0.396 100.0% 65.0% 20.0%        
1 VN-2 14 0.406 100.0% 63.3% 20.0%        
2 JWE-2 14 0.442 100.0% 61.7% 20.0%        
2 cH1N1 na 0.471 100.0% 60.0% 20.0%        
2 H1N2A na 0.478 100.0% 60.0% 10.0%        
2 WS-2 22 0.503 100.0% 60.0% 0.0%        
1 WS-1 33 0.54 100.0% 58.3% 0.0%        
1 WS-2 33 0.542 100.0% 56.7% 0.0%        
2 WS-1 22 0.674 100.0% 55.0% 0.0%        
1 JWE-1 22 0.687 100.0% 53.3% 0.0%        
 
Reported cutoff value, specificity, and sensitivity are shaded grey  
 
57 
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ABSTRACT 
Translation of influenza A virus PB1-F2 occurs in a second open reading frame (ORF) of 
the PB1 gene segment. PB1-F2 has been implicated in regulation of polymerase activity, 
immunopathology, susceptibility to secondary bacterial infection, and induction of 
apoptosis. Experimental evidence of PB1-F2 molecular function during infection has 
been primarily collected from human and avian viral isolates. As the 2009 H1N1 
(H1N1pdm09) strain highlighted, some swine-derived influenza viruses have the capacity 
to infect human hosts and emerge as a pandemic. Understanding the impact that virulence 
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factors from swine isolates have on both human and swine health could aid in early 
identification of viruses with pandemic potential. Studies examining PB1-F2 from swine 
isolates have focused primarily on H1N1pdm09, which does not encode PB1-F2, but was 
engineered to encode a full-length PB1-F2 ORF to assess the impact on viral replication 
and pathogenicity. However, experimental evidence of PB1-F2 protein expression from 
swine-lineage viruses has not been demonstrated. Here we reveal that during infection, 
PB1-F2 expression levels are substantially different between swine and human influenza 
viruses. We provide evidence that PB1-F2 expression is regulated at the translational 
level, with very low levels of PB1-F2 expression from swine-lineage viruses relative to a 
human isolate PB1-F2. Translational regulation of PB1-F2 expression was mapped to two 
independent regions within the PB1 mRNA, located within and downstream of the PB1-
F2 ORF. Our data suggest that encoding a full-length PB1-F2 ORF may not be predictive 
of PB1-F2 expression in infected cells for all influenza A viruses. 
 
INTRODUCTION 
Translation of influenza A virus (IAV) PB1-F2 initiates in a +1 open reading 
frame (ORF) relative to the PB1 gene via a leaky-ribosomal scanning mechanism as a 
result of the 43S ribosomal complex bypassing the PB1 start codon and two additional 
intervening AUG codons that translate short ORFs (sORFs) (1, 2). Previously, Wise et al. 
showed that PB1-F2 translation initiation is regulated as a result of differences in Kozak 
sequence strength, with the PB1 and two intervening sORF start codons having weak to 
moderate strength Kozak sequences, while the PB1-F2 ORF start codon has a strong 
Kozak sequence (2). Leaky-ribosomal scanning, in combination with reinitiation of PB1 
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mRNA is also responsible for translation of a third protein known as N40, which is 
encoded from a fifth AUG located in the same ORF as the PB1 gene but missing 39 
amino (N)-terminal amino-acids from the PB1 protein (3). Modification of the upstream 
start codons, Kozak sequences, and ORF nucleotide length has been shown to affect the 
level of PB1-F2 expression (2, 3). 
In early studies, PB1-F2 was found to have pro-apoptotic activity when expressed 
either independently or during influenza infection. Chen et al. first determined that PB1-
F2 was pro-apoptotic either when exposed to cells in synthetic form, or in the context of 
cells infected with either wildtype or PB1-F2 deficient A/Puerto Rico/8/34 (PR8) IAV 
(1). In addition, the carboxyl (C)-terminal portion of PB1-F2 has also been shown to 
interact with mitochondrial antiviral stimulating protein (MAVS), resulting in decreased 
mitochondrial membrane potential, and prevention of transcriptional upregulation of type 
I interferon (IFN) as well as other interferon stimulated genes (4, 5). Conversely, other 
studies have shown that PB1-F2 promotes the production of type I IFN, particularly IFN-
β, in human lung epithelial cells and is detrimental to successful virus infection (6). PB1-
F2 has also been shown to increase susceptibility to secondary bacterial infection through 
promotion of pro-inflammatory cytokine expression, which leads to increases in viral and 
bacterial replication rates, infiltration of monocytes into the lungs, severity of disease, 
and mortality (7-10). These divergent findings may suggest that IFN modulation 
properties of PB1-F2 are cell type or virus isolate specific.  
PB1-F2 proteins from different IAV isolates do not possess each function 
described for the protein. In fact, much of the molecular work done on PB1-F2 has been 
performed using a limited number of viral isolates, such as PR8, A/WSN/1933 (WSN), 
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A/Brevig Mission/1918 (1918 Spanish flu), and avian H5N1 isolates (1, 7, 11, 12). 
Because full length PB1-F2 ORFs are present at varying levels of prevalence in IAV it is 
necessary to have a complete understanding of how PB1-F2 from IAV isolated from 
different host species contributes to IAV replication or virulence. The 2009 swine origin 
H1N1 pandemic virus (H1N1pdm09) was a stark reminder that swine-derived IAV is 
capable of infecting and adapting to humans and emerging as a pandemic (13). Although 
not highly pathogenic, H1N1pdm09 illustrates the potential threat that swine IAV poses 
to human health (14). While H1N1pdm09 did not express full-length PB1-F2, recent IAV 
reassortants between H1N1pdm09 and H3N2 strains circulating in swine herds have 
infected humans (H3N2v strains), and although these viruses do not appear to have the 
capacity to transmit from human-to-human, they do appear to encode the capacity to 
express PB1-F2 (15). Thus, it is necessary to have a proper understanding of the 
molecular function and virulence potential of swine isolate-derived PB1-F2 proteins.  
The majority of published studies examining the function of swine PB1-F2 have 
focused on measuring phenotypic differences in vitro and in vivo using wildtype isolates 
or recombinant H1N1pdm09 viruses engineered to encode a full length PB1-F2 ORF. 
Conclusions of PB1-F2 effects on swine IAV infection from these studies are conflicted. 
For example, Hai et al. and Pena et al. found that restoring the PB1-F2 coding sequence 
to H1N1pdm09 resulted in increased growth kinetics and higher viral titers in cell culture, 
while Ozawa et al. illustrated that the presence of PB1-F2 had no affect on viral 
replication in vitro (16-18). Restoration of the PB1-F2 coding sequence had little to no 
effect on viral pathogenicity in infected mice, ferrets, or pigs in these studies, although a 
slight increase in pathogenicity was noted at early times in infection of pigs (16-18). 
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Other work using recombinant A/swine/Wisconsin/14094/99 viruses showed an increase 
of virus replication in primary alveolar macrophages but no differences in viral 
replication or pathogenicity in swine tissue explants or infected pigs (19). In all of the 
studies examining PB1-F2 function in swine IAV infection, PB1-F2 protein expression 
was not evaluated either in vitro or in vivo.  
In this study, we have determined that PB1-F2 protein expression from 
representative swine isolates is substantially decreased relative to a previously highly 
studied human isolate Additionally, we determined that PB1-F2 expression is regulated at 
the level of translation and identified two elements downstream from the PB1-F2 AUG 
that are involved in this regulation.  
MATERIALS AND METHODS 
Phylogenetic comparison of PB1-F2 nucleotide sequence. IAV PB1-F2 nucleotide 
coding sequences (nucleotides 119-391) from A/swine/Ohio/511445/2007(H1N1) 
(OH07), A/Mexico/4108/2009(H1N1) (Mx09), A/swine/Nebraska/02013/2008(H1N1), 
A/swine/Indiana/A00968373/2012(H3N2), A/Puerto Rico/8/1934(H1N1) (PR8), 
A/Brevig Mission/1/1918(H1N1) (1918 Spanish Flu), A/Viet NAM/1203/2004(H5N1) 
and A/Indonesia/CDC1047/2007(H5N1) were collected from NCBI. Additionally, using 
the Influenza Virus Resource database tool (NCBI), a nucleotide consensus sequence of 
swine PB1-F2 was established by comparing 310 unique PB1-F2 coding sequences from 
H1N1 and H3N2 viruses isolated from pigs in North America from 2000 to present. A 
phylogram was then created using Phylogeny.fr (20, 21) and annotated using Adobe 
Illustrator (Abobe). 
Cells and Reagents. MDCK (Madin-Darby canine kidney) and PK-15 (porcine kidney 
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epithelial) cells were maintained in EMEM (Eagle's modified essential medium, 
Mediatech). A549 (human alveolar basal epithelial) cells were maintained in F-12K 
Medium (Kaighn's Modification of Ham's F-12 Medium, Mediatech). 293T (human 
embryonic kidney) cells were maintained in Opti-MEM (Life Technologies). CEF 
(chicken embryo fibroblast) cells were maintained in DMEM (Dulbecco's modified 
essential medium, Life Technologies). 3D4/2 (porcine alveolar macrophage) were 
maintained in RPMI-1640 medium (ATCC). All cell culture media was supplemented 
with 10% FBS (Atlanta Biologicals) and penicillin/streptomycin (100 UI/ml, Mediatech). 
Primary antibodies used in this study include: mouse α-NP (ATCC) (22), rabbit α-PR8 
PB1-F2 (Peter Palese, Mount Sinai School of Medicine), rabbit α-OH07 PB1-F2 
(GenScript, peptide antibody against OH07 amino-acids 13-26), goat α-PB1 (Santa Cruz 
Biotechnology, Inc.), mouse α-3xFLAG (Sigma-Aldrich), and rabbit α-β-actin (Cell 
Signaling Technologies). Secondary antibodies used in immunofluorescence and 
immunoblotting experiments in this study are as follows: Alexa 350-, Alexa 488-, or 
Alexa 594-conjugated donkey or goat α-mouse, α-rabbit, α-goat, or α-human IgG 
antibodies (Life Technologies), and alkaline phosphatase-conjugated goat α-mouse, α-
rabbit, or rabbit α-goat (Bio-Rad Laboratories). MG132 at a final concentration of 0.5 
µM was added to cells where indicated. 
Viruses and Recombinant viruses. A/swine/OH/511445/2007 (OH07), A/Puerto 
Rico/8/1934 (PR8), and A/Mexico/4108/2009 (Mx09; Alexander Klimov, CDC) were 
used to represent H1N1 swine, human, and pandemic 2009 isolates, respectively. Eight 
reverse genetics plasmids for PR8 (Dr. Richard Webby, St. Jude Children's Research 
Hospital (23)) and Mx09 (Dr. Daniel Perez, University of Maryland) were used for 
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creation of recombinant viruses as previously described (23). The 11 amino-acid 
truncated Mx09 PB1-F2 sequence was replaced by the full-length OH07 PB1-F2 ORF 
sequence in the Mx09 PB1 gene to create PB1/MOM (see detailed construction below). 
Utilizing parental or mutant reverse genetics plasmids, recombinant viruses rMx09, 
Mx09+MOM PB1 (rMx/MOM), Mx09+PR8 PB1 (rMx/PR8), rPR8, and PR8+MOM 
PB1 (rPR8/MOM) were created. 
Plasmid construction.  
Reverse genetics plasmids. The OH07 PB1 gene sequence was amplified from virus stock 
by RT-PCR using universal primers that have been previously described (24). The 
resulting PCR product and pHW2000 were digested with BsmBI and ligated to create 
pHW2000/OH07/PB1. To create pDP2002/MOM/PB1, the OH07 PB1-F2 ORF was PCR 
amplified using gene-specific primers flanking the PB1-F2 sequence and 
pHW2000/OH07 PB1 as template. The resulting PCR product and pDP2002/Mx09/PB1 
plasmid were digested with BciVI and BstAPI and ligated. 
Expression plasmids. To create pOH07/PB1-F2/EGFP and pPR8/PB1-F2/EGFP, PB1-F2 
sequence from pHW2000/OH07/PB1 and pHW2000/PR8/PB1 was amplified using gene-
specific primers containing XhoI and HindIII restriction sites. pEGFP-N1 and 
amplification products were digested with XhoI and HindIII and ligated. pOH07/PB1-
F2/pET21a was created by PCR using gene-specific primers containing NdeI and XhoI 
digestion sites and pHW2000/OH07/PB1 as template. The resulting PCR product and 
pET21a were digested with NdeI and XhoI and ligated. To create pOH07/PB1-
F2/3xFLAG, gene-specific 3xFLAG tag containing forward and reverse primers and 
pHW2000/OH07/PB1-F2 template were used to amplify PB1-F2. The resulting PCR 
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product and pCi-Neo were digested with XhoI and XbaI and ligated. pPR8/PB1-
F2/3xFLAG was created by inserting annealed oligonucleotides containing the 3xFLAG 
tag flanked by KpnI and XbaI sites into KpnI and XbaI digested pPR8/PB1-F2/EGFP.  
Translational mapping plasmids. pOOO/3xFLAG and pMOM/3xFLAG were created by 
inserting annealed oligonucleotides containing the 3xFLAG tag flanked by PasI and 
BstAPI sites into PasI and BstAPI digested pHW2000/OH07/PB1 and 
pDP2002/MOM/PB1. pPPP/3xFLAG was created by PCR amplification using gene 
specific primers and pPR8/PB1-F2/3xFLAG as a template. The amplified product was 
ligated into pHW2000/PR8/PB1 using BstAPI and BfuAI digestion sites. 
pMMM/3xFLAG was created using gene specific primers and pDP2002/Mx09/PB1 and 
pMOM/3xFLAG as templates in an overlap PCR reaction. The resulting product was 
inserted into pDP2002/Mx09/PB1 using BsaAI and BstAPI sites. pMxKI/3xFLAG was 
created using pMMM/3xFLAG as a template in overlap PCR mutagenesis to remove stop 
codons within PB1-F2 (25). Nucleotides that introduced stop codons were replaced with 
the following: 152A to C, 291A to G, and 381A to G. The PCR product was then  
ligated into pDP2002/Mx09/PB1 using BsaAI and BstAPI restriction sites. Additional 
translational plasmids constructed for this study to map PB1-F2 translational regulatory 
regions are depicted in Table 1. The vector, insert PB1 nucleotide sequence, and methods 
used to create each plasmid are shown. These methods include PCR amplification with 
gene specific primers, overlap PCR using gene specific primers for amplification and 
fusion of sequences (25), and subcloning between plasmids containing identical 
restriction sites. All plasmids were selected by restriction digest and confirmed by 
sequencing. Primer sequences are available upon request. 
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 Table 1. 3xFLAG translational mapping plasmids 
Plasmid Vector Insert1 Restriction sites Method
2 
pPOP/3xFLAG pHW2000/PR8/PB1 pOOO/3xFLAG (nt 71-444) BstAPI, BfuAI P 
pMPM/3xFLAG pDP2002/Mx09/PB1 pDP2002/Mx09/PB1 (nt 1-391);  pPPP/3xFLAG (nt 392-445) BsaAI, BstAPI O 
pOPO/3xFLAG pHW2000/OH07/PB1 pHW2000/OH07/PB1 (nt 1-391); pPPP/3xFLAG (nt 392-445) BsaAI, BstAPI O 
pPPM/3xFLAG pDP2002/Mx09/PB1 pPPP/3xFLAG (nt 1-391);  pDP2002/Mx09/PB1 (nt 392-445) BsaAI, BstAPI O 
pPOM/3xFLAG pDP2002/Mx09/PB1 pPOP/3xFLAG (nt 1-391);  pDP2002/Mx09/PB1 (nt 392-445) BsaAI, BstAPI O 
pPPO/3xFLAG pHW2000/OH07/PB1 pPPO/3xFLAG (nt 1-391);  pH2002/OH07/PB1 (nt 392-445) BsaAI, BstAPI O 
pPOO/3xFLAG pHW2000/OH07/PB1 pPOO/3xFLAG (nt 1-391); pHW2000/OH07/PB1 (nt 392-445) BsaAI, BstAPI O 
pMOO/3xFLAG pHW2000/OH07/PB1 pMOM/3xFLAG (nt 1-445) BsaAI, BstAPI P 
pOOM/3xFLAG pDP2002/Mx09/PB1 pOOO/3xFLAG (nt 1-445) BsaAI, BstAPI P 
pMPO/3xFLAG pHW2000/OH07/PB1 pMPM/3xFLAG (nt 1-445) BsaAI, BstAPI P 
pOPM/3xfLAG pDP2002/Mx09/PB1 pOPO/3xFLAG (nt 1-445) BsaAI, BstAPI P 
pMOP/3xFLAG pHW2000/PR8/PB1 pMOM/3xFLAG (nt 1-444) NheI, BfuAI P 
pMPP/3xFLAG pHW2000/PR8/PB1 pMPM/3xFLAG (nt 1-444) NheI, BfuAI P 
pOOP/3xFLAG pHW2000/PR8/PB1 pOOO/3xFLAG (nt 1-444) NheI, BfuAI P 
pOPP/3xFLAG pHW2000/PR8/PB1 pOPO/3xFLAG (nt 1-444) NheI, BfuAI P 
pMPM(P1121-
2298)/3xFLAG pMPP/3xFLAG pMPM/3xFLAG (nt 1-1140) NheI S 
pMPM(P392-
1140M)3xFLAG pMPM/3xFLAG pMPP/3xFLAG (nt 1-1140) NheI S 
pMPM(P392-
816)/3xFLAG pDP2002/Mx09/PB1 pMPM(P392-1140M)3xFLAG (nt 1-817) BsaAI, HindIII P 
pMPM(P392-
586)/3xFLAG 
pMPM(P392-
816)/3xFLAG pDP2002/Mx09/PB1 (nt 583-817) BsmBI, HindIII P 
pMPM(P582-
816)/3xFLAG 
pMPM(P392-
816)/3xFLAG pMPM/3xFLAG (nt 1-582) BsaAI, BsmBI P 
pMO(P267-
391)M/3xFLAG pDP2002/Mx09/PB1 
pMOM/3xFLAG (nt 1-266); 
pMPM/3xFLAG (nt 267-445) BsaAI, BstAPI O 
pM(P119-
252)OM/3xFLAG pDP2002/Mx09/PB1 
pMPM/3xFLAG (nt 1-252);  
pMOM/3xFLAG (nt 253-445) BsaAI, BstAPI O 
pMO(P344-
816)M/3xFLAG  pDP2002/Mx09/PB1 
pMOM/3xFLAG (nt 1-336);  
pMPM(P582-816)/3xFLAG (nt 337-817) 
BsaAI, EcoRI, 
HindIII P 
pMO(P267-335)O(P392-
816)M/3xFLAG pDP2002/Mx09/PB1 
pMO(P267-391)M/3xFLAG (nt 1-336); 
pMOP/3xFLAG (nt 337-817) 
BsaAI, EcoRI, 
HindIII P 
pMOMF2UP/3x 
FLAG 
pMPM(P392-
816)/3xFLAG 
pMO(P267-335)O(P392-816)M/3xFLAG  
(nt 1-336); pMOM/3xFLAG (nt 337-582) 
BsaAI, EcoRI, 
BsmBI P 
pPP(O267-
343)P/3xFLAG pHW2000/PR8/PB1 
pPPP/3xFLAG (nt 71-266);pMO(P344-
816)M/3xFLAG (nt 267-444) BstAPI, BfuAI O 
pPR8F2dwn/3x 
FLAG 
pPP(O267-
343)P/3xFLAG 
pDP2002/Mx09/PB1 (nt 583-817); 
pHW2000/PR8/PB1 (nt 818-1134) 
BsmBI, HindIII, 
PstI P 
1: Numbers correspond to the PB1 nucleotides inserted from parent plasmid(s) into the vector and are in reference to the beginning of 
the 5ʹ influenza UTR prior to the PB1 mRNA sequence. Does not include 3xFLAG sequence. 
2:Method used to generate insert PCR (P), overlap PCR (O), and subcloning (S) 
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Production of Recombinant PB1-F2. Rosetta E. coli were transformed with 
pOH07/PB1-F2/pET21a using an Eppendorf Multiporator (Eppendorf) set to 1700 V with 
a time constant of 5 ms. Cells were resuspended in 1 ml of Luria broth (LB), incubated in 
a 37 °C shaking incubator for 30 min, and plated on Luria agar containing 50 µg/ ml 
ampicillin (AMP) for overnight incubation at 37 °C. Colonies were picked and grown in 
LB containing 50 µg/ ml AMP. The following day, cultures were diluted 1:100 in the 
same media formulation with the addition of 1 mM isopropyl β-D-l-
thiogalactopyranoside (IPTG) for 4 h. Pellets were collected and purified using a 
BioLogic protein puriﬁcation system (26). Expression of PB1-F2 in each 5 ml fraction of 
the purified protein was confirmed using immunoblot. 
Infections and Transfections. MDCK, A549, PK-15, 3D4/2, or CEF cells were plated to 
a final density of 2.5 x 105/well (6-well plate) or 5 x 105/60-mm dish, and 293T cells to a 
final density of 2 x 106/60 mm dish for transfections and infections. Infections were 
carried out using EMEM or F-12K media containing 0.4% bovine serum albumin (BSA), 
penicillin/streptomycin (100 UI/ml), and 1 µg/µl TPCK-treated trypsin. Viral titers were 
determined for each cell line using TCID50 and a PFU/ml working estimate was 
calculated (PFU/ml=TCID50*0.7; ATCC 
[www.atcc.org/common/technicalInfo/faqAnimalVirology.cfm#Q5]). Infections were 
carried out at a multiplicity of infection (MOI) of either 2, for IF and RT-qPCR, or 5, for 
immunoblots. For PB1-F2 degradation assays, infected MDCK cell were incubated with 
MG132 for four hours prior to harvest. MDCK, A549, and PK-15 cells were transfected 
using Lipofectamine 2000 (Invitrogen) and 293T cells were transfected using TransIT-
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LT1 (Mirus) per manufacturer's instructions.  
Immunofluorescence microscopy. Cells plated on coverslips were transfected for 24 h 
or infected for indicated times, then fixed with 4% paraformaldehyde in phosphate 
buffered saline [(PBS; 137 mM NaCl, 3 mM KCl, 8 mM Na2HPO4 (pH 7.5)], 
permeabilized with PBS containing 0.2% Triton-X and blocked by incubation in 2% BSA 
in PBS. Samples were incubated with primary antibodies in 2% BSA in PBS for 45 min, 
and washed three times with PBS-T, followed by incubation with secondary antibodies in 
2% BSA in PBS for 45 min. Cells were washed an additional three times with PBS and 
mounted on slides using Prolong Antifade with or without DAPI (Life Technologies). 
Stained cells were visualized using a Zeiss Axiovert 200 inverted microscope equipped 
with fluorescence optics and Axiovision software (Zeiss). Images were prepared using 
Adobe Photoshop and Illustrator software (Adobe). PB1-F2 expression was quantified by 
counting NP (infected) or PB1 (transfected) expressing cells, then counting PB1-F2 or 
3xFLAG expressing cells within this subset to determine the percentage of infected or 
transfected cells expressing PB1-F2. All quantifications were done in triplicate on 
independent experimental samples to calculate averages and standard deviation and for 
statistical comparison. 
RT-qPCR. MDCK cells were infected with either OH07 or PR8 virus for 12 h. Total 
RNA was extracted from each sample using TRIzol reagent per manufacturer's directions 
(Invitrogen). cDNA was created using Superscript III First-Strand Synthesis SuperMix 
(Invitrogen) with Oligo-dT primer. RNA was removed by treating samples with RNaseA 
for 3 h. Ten-fold serial dilutions of sample cDNA were quantified using iScript One-Step 
RT-PCR with SYBR green kit (Bio-Rad). Primers against either PB1 (Forward 5′-
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GGCCCTTCAGTTGTTCATC-3ʹ; Reverse 5ʹ-GCAGACTTCAGGAATGTG-3ʹ) or NP 
(Forward 5ʹ- GCGTCTCAAGGCACCAAAC-3ʹ; Reverse 5ʹ- 
TCAAAAGCAGAGAGCACCATT-3ʹ) were used for amplification of cDNA samples. 
The qPCR reaction mix for each sample consisted of 7.5µl 2X SYBR Green RT-PCR 
reaction mix, 5µl of nuclease-free water, 0.6µl of each primer, 0.3µl iScript RNase H+ 
reverse transcriptase and hot-start iTaq DNA polymerase mix, and 1µl of diluted cDNA 
template. The qPCR samples were detected with a MyiQ iCycler real-time PCR detection 
system (Bio-Rad) and carried out in triplicate in each experiment with two independent 
replicates performed using two OH07 and PR8 RNA samples sets for each replicate. 
Samples were then compared using the Pfaffl method in reference to PR8 readings (27). 
Immunoprecipitation. 20 µl of MagnaBind protein A beads (Thermo Scientific) per 
transfected sample was added to 400µl RAF buffer (20 mM Tris [pH 8.0], 137 mM NaCl, 
10% glycerol, 1% NP-40) containing Halt Protease Inhibitor cocktail (Thermo 
Scientific). Beads were washed three times with RAF buffer. Immunoprecipitating 
antibodies were added to aliquots of washed beads and incubated at 4°C with constant 
inversion mixing for 2 h. Antibody/bead complexes were washed six times and 
resuspended in 100ul per sample of RAF buffer. 48 h post-transfection, 293T cells were 
washed using PBS, harvested, and pelleted into a 1.5ml tube. 800ul of RAF buffer with 
protease inhibitors was added to each sample, and vortexed four times for 30s at 10 min 
intervals with incubation on ice between vortexing. Cellular debris from lysed transfected 
samples was removed by centrifugation and 400µl of supernatant was added to new 
1.5ml tubes with antibody/bead complexes. Samples were incubated at 4°C with constant 
inversion mixing overnight, then washed six times with RAF buffer with protease 
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inhibitors and resuspended in 15ul of 2xSDS-PAGE loading buffer (100mM Tris [pH 
6.8], 200mM dithiothreitol, 4% sodium dodecyl sulfate (SDS), 0.2% bromophenol blue, 
and 10% glycerol).  
Immunoblotting. Immunoprecipitated (IP) samples, infected cell lysates, or recombinant 
OH07 PB1-F2 protein were separated by 10% (PB1, actin) or 15% (PB1-F2; FLAG) 
Tris-glycine SDS polyacrylamide gel electrophoresis (SDS-PAGE). Gels were 
transferred via electroblotting in transfer buffer (25 mM Tris, 192 mM glycine, 20% 
methanol [pH 8.3]) onto 0.45um Nitrocellulose (BioRAD) at 70V for 70min. Membranes 
were blocked using 5% milk in Tris buffered saline with 0.5% Tween 20 (TBS-T) for 30 
min and incubated with 5% milk in TBS-T containing primary antibodies at room 
temperature overnight. Blots were washed three times with TBS-T and incubated for 4 h 
with the appropriate AP-conjugated secondary antibody in 1% milk in TBS-T. Blots were 
washed three times with TBS-T and exposed to chemiluminescent reagent (Lumiphos, 
Thermo Scientific). Images were captured using a ChemiDocXRS imager and Quantity 
One imaging software (BioRad). Images were processed using Adobe Photoshop and 
Illustrator software (Adobe). 
Statistical analysis. Samples from infection studies were compared using paired T-test 
analysis and statistically different groups (p-value[p]<0.05) are indicated. Translation 
clone and mapping studies were compared using single factor ANOVA analysis and were 
grouped based upon sequence and statistical significant groups (p<α-value=0.01) are 
indicated. All statistical analyses were computed using Excel 2007 with Analysis 
ToolPak add-on (Microsoft). 
RESULTS 
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Detection of swine PB1-F2 in transfected and infected cells. A phylogram was created 
comparing PB1-F2 nucleotide coding sequences from OH07, Mx09, PR8, a swine 
consensus sequence (derived from unique PB1-F2 sequences from 2000-present), 1918 
Spanish flu, two high pathogenic avian H5N1 isolates, and two other swine IAVs. 
Comparison of the OH07 PB1-F2 nucleotide sequence with a consensus and other swine 
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PB1-F2 sequences using the phylogram indicated that the OH07 PB1-F2 sequence used 
in our studies is highly representative of PB1-F2 sequence from swine influenza isolates, 
including a swine-origin H3N2 variant (H3N2v; A/Swine/Indiana/A00968373/2012) 
strain recently isolated from an infected pig. Moreover the phylogram indicates that 
swine PB1-F2 sequence is substantially different from isolates commonly used in studies 
examining PB1-F2 molecular function (PR8, 1918 or H5N1 viruses), suggesting there 
may be functional differences between swine and the previously studied PB1-F2 proteins 
during virus infection ( 1A).  
 In order to study swine PB1-F2 expression, peptide antibodies against OH07 PB1-
F2 amino acid sequence 13-26 (TEHTNIQKKGNGRQ) were obtained from a 
commercial vendor (GenScript). The antibody was first tested for its ability to recognize 
swine PB1-F2 in transfected cells. Plasmids were constructed that express OH07 PB1-F2 
fused in frame with a C-terminal EGFP (pOH07/PB1-F2/EGFP) or 3xFLAG tag 
(pOH07/PB1-F2/3xFLAG). MDCK cells were transfected with these plasmids and the 
fusion proteins were visualized using the OH07 PB1-F2 antibody, FLAG antibody, or the 
inherent fluorescence of EGFP. The PB1-F2 antibody staining revealed that the OH07-
derived fusion proteins were localized throughout the nucleus and cytoplasm of cells in a 
pattern that was identical to that of the FLAG antibody and EGFP fluorescence (Fig. 1B), 
strongly suggesting the antibody was recognizing the OH07 PB1-F2 fusion proteins. 
Additional plasmid constructs encoding N-terminal FLAG and EGFP PB1-F2 fusion 
proteins showed similar colocalization of the PB1-F2 antibody staining with the FLAG 
antibody or inherent EGFP (data not shown).  
 To examine swine PB1-F2 expression in infected cells, we wanted to utilize both 
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wildtype and recombinant viruses. However, for reasons that are unclear, we were unable 
to create a recombinant OH07 virus from reverse genetics plasmids despite multiple 
attempts using a variety of protocols. Because of this we instead developed a recombinant 
virus system in which we replaced the truncated PB1-F2 nucleotide sequences in the PB1 
reverse genetics plasmid from an H1N1pdm09 (Mx09) viral isolate with OH07 PB1-F2 
nucleotide sequence (nts 128-445, denoted PB1/Mexico/Ohio/Mexico, or 
pDP2002/MOM/PB1) (Fig. 1C). The seven other Mx09 plasmids plus 
pDP2002/MOM/PB1 were then transfected into cells to produce recombinant virus 
(rMx/MOM). MDCK, A549, and PK-15 cells were infected with wildtype OH07 
(wtOH07), Mx09, or rMx/MOM viruses and at 12 h p.i., cells were stained with 
antibodies against the NP protein and OH07 PB1-F2 to visualize swine PB1-F2 
expression in infected cells (Fig 1D). Distinct nuclear PB1-F2 staining was visible in 
some OH07 and rMx/MOM infected cells, whereas no PB1-F2 staining was detected in 
Mx09 infected cells, strongly suggesting our antibody specifically recognized swine PB1-
F2 in cells infected with wildtype and recombinant viruses expressing PB1-F2 from 
OH07. 
 PB1-F2 expression levels differ between viral isolates. Upon examination of PB1-F2 
expression in infected cells, we noticed a striking difference in the number of OH07 
infected cells expressing PB1-F2 relative to cells infected with the human lab adapted 
strain PR8. This led us to hypothesize that there may be a strain-specific difference in the 
number of infected cells expressing PB1-F2 between swine and human origin isolates. To 
examine this hypothesis, we infected cells with OH07, rMx/MOM, or rPR8, and 
quantified the number of infected cells expressing PB1-F2 in each sample over a 48 h 
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time course (Fig. 2A). 
Surprisingly, these studies 
suggested that at all times p.i, 
the number of cells expressing 
PB1-F2 in the swine virus 
infected samples (<1% 
infected cells expressing PB1-
F2 for every sample) were 
significantly lower than in the 
PR8 virus infected cells 
(peaking just over 14% of 
infected cells expressing PB1-
F2 at 12 h p.i.) (Fig. 2A). 
These experiments were 
repeated in A549, PK-15, 
3D4/2 and CEF cells with 
similar results (Fig. 2B, and 
data not shown), suggesting 
that this phenotype is not cell 
type specific. Levels of PB1-
F2 protein expression in cells 
infected with OH07 were 
further examined using 
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immunoblot analysis. In these 
experiments, although we could 
easily detect a recombinant 
OH07 PB1-F2 protein purified 
from bacterial cells with OH07 
PB1-F2 antibody, we were 
unable to detect OH07 PB1-F2 
from infected cells (Fig. 2C). To 
confirm that the low expression 
levels of PB1-F2 observed in 
these experiments were 
representative of swine IAV isolates, MDCK cells were infected for 12 h with two 
additional swine viruses that are predicted at the sequence level to express a full-length 
PB1-F2 protein (A/Swine/Nebraska/02013/2008(H1N1) or 
A/Swine/Indiana/A00968373/2012(H3N2)) and the percentage of PB1-F2-expressing 
infected cells was determined. Similar to OH07, less than 0.5% of cells infected with 
these swine viruses expressed PB1-F2 (data not shown) suggesting that low expression of 
PB1-F2 is a common swine IAV phenotype.  
Strain-specific differences in PB1-F2 expression are dependent on the PB1 gene. To 
determine if any of the other IAV gene segments impact the differential PB1-F2 protein 
levels measured in Fig. 2, additional recombinant viruses were constructed which 
combined either the PR8 PB1 gene with the seven other Mx09 gene segments (rMx/PR8), 
or the MOM PB1 gene with the seven other PR8 gene segments (rPR8/MOM). MDCK 
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cells were inoculated with rPR8, rMx/PR8, rMx/MOM, or rPR8/MOM and at 12 h p.i., 
cells were immunostained and the percentage of infected cells expressing PB1-F2 was 
determined (Fig. 3). While there was a small but significant (p<0.05) decrease in the 
number of cells expressing PB1-F2 in the rMx/PR8 virus infected cells relative to rPR8, 
there was no significant increase in the number of cells expressing PB1-F2 in the 
rPR8/MOM relative to rMx/MOM infected cells. Moreover, the rPR8 and rMx/PR8 
infected cells had far increased numbers of PB1-F2-expressing cells when compared to 
rMx/MOM or rPR8/MOM infected cells. These results strongly suggest that differences 
outside of the PB1 gene do not contribute substantially to PB1-F2 protein expression 
levels. Taken together with results in Fig. 2A, these findings suggest that PB1-F2 
expression levels are differentially regulated between influenza isolates, in a manner 
dependent on the PB1 gene and independent of cell line and virus genetic backbone. 
Importantly, this data also suggests that these isolates of swine influenza virus do not 
express substantial amounts of PB1-F2, even though they encode the capacity to do so at 
the nucleotide level.  
PB1-F2 expression is regulated at the level of translation. To identify the step in 
which PB1-F2 expression is differentially regulated in PR8 versus OH07, we examined 
PB1 mRNA levels and PB1-F2 protein stability in infected cells. In order to determine if 
OH07 PB1 mRNA levels were significantly decreased relative to PR8, MDCK cells were 
infected with rPR8 or wtOH07 at an MOI of 2. At 12 h p.i., total RNA was isolated from 
infected cells and subjected to reverse transcription and RT-qPCR using PB1 and NP 
gene-specific primers to determine the OH07 PB1/NP RNA ratios relative to PR8 in 
infected cells (Fig. 4A). These experiments indicated that the wtOH07 infected cells 
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contained slightly higher PB1/NP 
mRNA ratios when compared to 
rPR8 infected samples, 
suggesting that decreased OH07 
PB1-F2 protein levels do not 
result from a decrease in PB1 
mRNA levels. 
 It has previously been 
reported that the PB1-F2 protein 
from some IAV isolates is 
unstable and in some cases can be 
stabilized by pharmaceutical 
inhibition of the proteasome (1). 
To determine the inherent 
stability of the OH07 PB1-F2 
protein, we investigated its 
accumulation in the absence and 
presence of proteasome 
inhibition. While we measured a 
significant increase in the number 
of rPR8 infected cells expressing 
PB1-F2 following proteasome 
inhibition (p<0.05), MG132 had 
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no significant effect on the number of cells expressing PB1-F2 in wtOH07 infected cells 
(Fig. 4B). These findings illustrate that the low expression levels of the OH07 swine 
PB1-F2 protein are not a result of inherent instability of the protein. Taken together with 
data in Fig. 4A, these findings indicate that the diminished levels of PB1-F2 protein in 
swine influenza virus infected cells are a result of decreased synthesis of the protein 
suggesting PB1-F2 protein translation may be differentially regulated in an isolate 
specific manner. 
Validation of a plasmid-based system to identify PB1 sequences involved in 
regulation of PB1-F2 expression. In order to determine if specific sequences within the 
PB1 gene played a role in differentially regulating PB1-F2 protein expression between 
influenza isolates, we developed a method to evaluate PB1-F2 expression independent of 
infection using plasmid expression vectors. Parental plasmids were constructed from the 
full-length PB1 gene in the reverse genetics plasmid backbones of OH07 
(pOOO/3xFLAG), PB1/MOM (pMOM/3xFLAG), and PR8 (pPPP/3xFLAG) in which a 
3xFLAG tag was inserted in frame at the C-terminus of the PB1-F2 ORF (Fig. 5A). The 
insertion of the 3xFLAG tag resulted in the addition of 25 non-PB1 amino-acids between 
residues 121 and 122 of the PB1 protein, but did not disrupt the PB1 protein ORF. In 
order to validate our plasmid-based translational system, we examined the expression 
levels of PB1-F2/3xFLAG relative to PB1 using pPPP/3xFLAG, pOOO/3xFLAG, and 
pMOM/3xFLAG plasmids. MDCK cells were transfected with each plasmid, and at 24 h 
post-transfection, cells were fixed and immunostained with FLAG and PB1-specific 
antibodies. Cells expressing PB1 were examined for PB1-F2/3xFLAG protein 
expression, and the number of cells expressing PB1-F2/3xFLAG relative to the total 
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number of PB1 expressing cells was determined. In these experiments, similar to what 
was measured in infection, cells transfected with pPPP/3xFLAG expressed PB1-F2 in a 
much higher percentage of cells (66%) than either pOOO/3xFLAG (13%) or 
pMOM/3xFLAG (11%) (Fig. 5B). To confirm this data, immunoprecipitations (IP) of 
PB1-F2/3xFLAG and PB1 proteins expressed in transfected 293T cells was performed 
using 3xFLAG and PB1 specific antibodies, and protein expression levels were analyzed 
using immunoblot analysis. Again, while cells transfected with pPPP/3xFLAG expressed 
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detectable levels of PB1-F2, there was no detectable PB1-F2 expression in 
pOOO/3xFLAG or pMOM/3xFLAG transfected cells. The levels of PB1 protein 
immunoprecipitated between plasmids were similar, suggesting the differences in PB1-F2 
protein expression from these plasmids was specific to the PB1-F2 ORF (Fig. 5C).  
Based on the similarity between OH07 and Mx09 sequences (Fig. 1A), we 
hypothesized that knock-in of PB1-F2 in Mx09 may not result in substantial increases in 
PB1-F2 expression. To examine this, we created a plasmid in which single nucleotide 
changes in the third position of the premature stop codons within the Mx09 PB1-F2 ORF 
were replaced with coding sequence (152A to C, 291A to G, and 381A to G), and cloned 
into the PB1/3xFLAG plasmid backbone (pMxKI/3xFLAG; Fig 5A). Similar to 
OOO/3xFLAG and MOM/3xFLAG, levels of PB1-F2 expression from the 
MxKI/3xFLAG plasmid were very low in transfected cells when compared to 
PPP/3xFLAG (Fig. 5B and 5C), suggesting that reintroduction of the full-length PB1-F2 
ORF into the Mx09 PB1 gene does not result in substantial expression of PB1-F2.  
The PB1-F2 ORF and downstream PB1 sequences regulate PB1-F2 expression 
levels. To determine if sequences in the PB1 gene play a role in regulation of PB1-F2 
expression, PB1-F2/3xFLAG plasmids were constructed in which the PB1 gene was 
divided into three regions: the 5ʹ region prior to the PB1-F2 AUG (5ʹ PB1), the PB1-F2 
ORF (F2 ORF), and the 3ʹ region downstream of the PB1-F2 stop codon (3ʹ PB1). 
Utilizing this approach, all possible combinations of these PB1 chimeric genes were 
created between Mx09, PR8, and OH07 (Fig. 6A). Each construct was named based on 
the first letter of the virus from which each PB1 sequence section is derived. For 
example, the parental PR8 plasmid described above is denoted pPPP/3xFLAG because 
80 
 
the 5ʹ region 
before the PB1-F2 
ORF is from PR8, 
the PB1-F2 ORF is 
from PR8, and the 
3ʹ region following 
the PB1-F2 stop 
codon is from 
PR8.  
 Each of the 
chimeric plasmids 
were transfected 
into MDCK cells 
and at 24 h post-
transfection, cells 
were fixed and 
stained with PB1- 
and FLAG-
specific antibodies 
and the percentage 
of cells expressing 
PB1 that also 
expressed PB1-F2/3xFLAG was determined. PB1-F2 expression from these plasmids fit 
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into three distinct groups including low expressers (13-18% positive cells), medium 
expressers (26-38% positive cells) and high expressers (59-66% positive cells) (Fig 6B). 
Grouping of the low, medium, and high PB1-F2 expressing plasmids resulted in the 
identification of a clear pattern of PB1-F2 expression. The 5ʹ region upstream of PB1-F2, 
which harbors the PB1 AUG and Kozak sequence, 2 additional AUGs that encode short 
ORFs, and the PB1-F2 Kozak sequence, had no significant impact on numbers of cells 
expressing PB1-F2 in this system, as low, medium, and high expressers were found to 
have this region from both swine and PR8 origin. However, when both the F2 ORF and 
3′ PB1 regions originated from swine-lineage gene segment 2 (OH07, Mx09), PB1-F2 
expression was low. Similarly, when both the F2 ORF and 3ʹ PB1 regions originated 
from PR8, PB1-F2 expression was high. Finally, when the origins of the F2 ORF and the 
3ʹ PB1 regions were mixed (one swine origin and one PR8 origin) PB1-F2 was expressed 
at a medium level. Thus, sequences within the F2 ORF and the 3′ PB1 regions play roles 
in regulation of PB1-F2 expression from the influenza A virus PB1 gene.  
PB1 nucleotides 267-335 and 582-816 are necessary and sufficient to modulate PB1-
F2 protein expression. In order to identify specific sequences within the F2 ORF and 3ʹ 
PB1 region involved in regulation of PB1-F2 expression, a series of additional plasmids 
were constructed using the MPM/3xFLAG (medium expresser) plasmid as the parent and 
making incremental swaps of swine and PR8 origin sequence within one or both of these 
regions. To examine the 3′ PB1 region, it was first divided into half and Mx09 nts 392-
1140 [pMPM(P392-1140)/3xFLAG] or 1131-2298 [pMPM(P1131-2298)/3xFLAG] from 
MPM/3xFLAG were replaced with the same sequence from PR8 (Fig. 7A). While 
pMPM(P1131-2298)/3xFLAG remained a medium expresser like the parent plasmid, 
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pMPM(P392-1140)/3xFLAG expressed PB1-F2 at high levels, implicating PB1 nts 392-
1140 in PB1-F2 translational regulation (Fig. 7A). PB1 nts 392-816 [pMPM(P392-
816)/3xFLAG] and 392-586 [pMPM(P392-586)/3xFLAG] from Mx09 were then 
replaced with PR8 sequence in the pMPM/3xFLAG construct and tested for PB1-F2 
expression. pMPM(P392-816)/3xFLAG was a high expresser, however pMPM(P392-
586)/3xFLAG was a medium expresser, suggesting that PB1 nts 587-816 were necessary 
for PB1-F2 translational regulation. To determine if PB1 nts 587-816 were sufficient for 
modulation of PB1-F2 expression, PR8 PB1 nts 582-816 were cloned into 
pMPM/3xFLAG [pMPM(P582-816)/3xFLAG]. This plasmid was also found to be a high 
PB1-F2 expresser. These data implicate PB1 nts 582-816 in the 3ʹ PB1 region as being 
necessary and sufficient in differential regulation of PB1-F2 translation. 
 A similar strategy was taken to map the F2 ORF translational regulatory element. 
In these experiments the MOM/3xFLAG plasmid was initially used as the parental 
construct. Clones were made in which OH07 PB1 nts 119-252 [pM(P119-
252)OM/3xFLAG] or 267-391 [pMO(P267-391)M/3xFLAG] from pMOM/3xFLAG 
were replaced with PR8 PB1 nts, and PB1-F2 expression was measured as previously 
described (Fig. 7B). While pM(P119-252)OM/3xFLAG remained a low expresser, 
pMO(P267-391)M/3xFLAG expressed medium levels of PB1-F2, suggesting PB1 nts 
267-391 modulate PB1-F2 translation (Fig. 7B).  
Combining findings from 5ʹ PB1 mapping with F2 ORF mapping, PR8 PB1 nts 
344-816 in pMOM/3xFLAG were replaced with OH07 sequence [pMO(P344-
816)M/3xFLAG]  which resulted in a decrease of PB1-F2 expression to medium levels. 
In contrast, replacing OH07 PB1 nts 267-335 with PR8 sequence [pMO(P267-
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335)O(P392-816)M/3xFLAG]  resulted in high level expression of PB1-F2. Likewise, 
replacing PR8 PB1 nts 267-343 with OH07 sequence in the pPPP/3xFLAG parent 
[pPP(O267-343)P/3xFLAG] resulted in medium levels of PB1-F2 expression. Altogether, 
these findings suggest PB1 nts 267-335 within the PB1-F2 ORF are necessary and 
sufficient for PB1-F2 translational modulation.  
Using the above data, two final plasmids encoding the minimal sequences 
identified above for increasing PB1-F2 expression to high levels in the pMOM/3xFLAG 
background (pMOMF2up/3xFLAG, nts 267-335 and 582-816 from PR8 PB1 into 
OH07/Mx09 PB1), or alternatively for decreasing PB1-F2 expression to low levels in the 
pPPP/3xFLAG background (PR8F2down/3xFLAG, nts 267-343 and 587-819 from 
OH07/Mx09 PB1 into PR8 PB1; nucleotide sequence discrepancies between these clones 
are the result of the availability of restriction digestion sites) were created and tested for 
PB1-F2 expression (Fig 7C). MDCK cells transfected with pMOMF2up/3xFLAG 
expressed the swine-like PB1-F2 protein in similar numbers of cells as pPPP/3xFLAG 
transfected cells. Moreover, MDCK cells transfected with pPR8F2down/3xFLAG 
expressed the human like PB1-F2 protein in a similar number of cells as 
pMOM/3xFLAG, thus illustrating that these regions are necessary and sufficient to either 
increase or decrease the number of cells expressing PB1-F2 to either PR8 or OH07 PB1-
F2 levels, respectively. 
This data was confirmed with immunoprecipitation of PB1-F2/3xFLAG and PB1 
from 293T cells transfected with pMOM/3xFLAG, pMOMF2UP/3xFLAG, 
pPPP/3xFLAG, or pPR8F2dwn/3xFLAG followed by immunoblot assay using 3xFLAG 
antibodies (Fig 7D). In these experiments, it is evident that pPR8F2dwn/3xFLAG is 
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expressing substantially lower levels of PB1-F2 than pPPP/3xFLAG. Likewise, 
pMOMF2up/3xFLAG is expressing substantially higher levels of PB1-F2 than 
pMOM/3xFLAG, supporting our findings that these sequences in the F2 ORF and 3' 
region are sufficient to differentially regulate PB1-F2 expression. However, these 
experiments also show that the total levels of PB1-F2/3xFLAG protein expressed in 
pMOMF2up/3xFLAG do not reach the levels expressed by pPPP/3xFLAG, suggesting 
that while these regions regulate the number of cells expressing PB1-F2, further 
regulation of total amounts of protein per cell may also be present. Altogether, this data 
shows that PB1-F2 expression levels are regulated at the translational level by two 
sequence elements within the F2 ORF and 3ʹ PB1 region and can be modified to 
modulate PB1-F2 expression in the influenza A PB1 gene. 
DISCUSSION 
Our data demonstrates that encoding a full-length PB1-F2 ORF is not predictive of 
expression of the protein during infection, and that IAV expresses dramatically different 
levels of the PB1-F2 protein in a strain-specific manner. In this study, we were only able 
to detect PB1-F2 derived from wildtype swine and recombinant MOM/PB1 strains of 
IAV in rare infected cells (less than 1%; Fig. 2A-B, Fig 3, and data not shown). Because 
of such low expression levels, the swine-derived protein may not have a measurable 
effect during infection in cells or animals. Our findings may help explain the lack of 
impact following introduction of the full-length PB1-F2 sequence into H1N1pdm09, as 
PB1-F2 expression was not demonstrated in the PB1-F2 knock-in mutants used in prior 
studies (16-18). Our data shows that the presence of the full-length PB1-F2 ORF in the 
IAV genome is not a predictor for PB1-F2 protein expression and suggests that restoring 
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the PB1-F2 protein coding sequence alone in viruses lacking a full-length ORF may not 
be sufficient to restore PB1-F2 expression. Additionally, inserting a PB1-F2 ORF 
sequence from one viral isolate into the genome sequence of another isolate, such as PR8, 
is likely also misleading with regards to the expression of the protein in its wildtype virus 
context because of the contribution of the 3ʹ PB1 translation element on PB1-F2 
expression. As shown here when the low-expressing OH07 PB1-F2 ORF was cloned into 
the PR8 PB1 gene (POP/3xFLAG), PB1-F2 was expressed at much higher levels than 
when it was present in a fully swine origin-derived PB1 gene (OOO/3xFLAG and 
MOM/3xFLAG). When such a chimeric gene is introduced into a recombinant virus, 
PB1-F2 may be expressed at higher levels than when located in its native PB1 gene 
context, and any phenotypic contribution to IAV infection attributed to PB1-F2 
expression would be skewed as a result. Thus it is necessary to consider all of the 
complexities of PB1-F2 translation in order to determine its level of expression and 
contribution, if any, to IAV infection. 
There is strong evidence that PB1-F2 protein translation is regulated at the level of 
ribosomal leaky-scanning and that altering the 5ʹ sequence upstream of the PB1-F2 ORF 
can modulate PB1-F2 expression. In particular, mutation of the third PB1 AUG such that 
translation initiation is prevented just prior to the PB1-F2 ORF results in increased 
expression of PB1-F2 (2). Indeed, we were able to recapitulate this finding in our studies 
(data not shown). However, because the Kozak sequences regulating this PB1-F2 
modulation are conserved between OH07/Mx09 and PR8, interchanging the 5ʹ PB1 
region using our chimeric PB1 translational clones had no effect on expression levels in 
our system. Instead, we have identified nucleotides 267-343 in the F2 ORF region and 
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nucleotides 582-816 in the 3ʹ PB1 region as additional contributors to the regulation of 
PB1-F2 translation. Our studies suggest that each region can be utilized to increase or 
decrease PB1-F2 expression but when both elements are present the effect on PB1-F2 is 
more dramatic. 
The mechanism by which the F2 ORF and 3ʹ PB1 regions affect PB1-F2 translation is 
currently not clear. The fact that these two regions can impact translation individually and 
additively suggests that the F2 ORF and 3ʹ PB1 regions are acting independently on 
translation regulation of PB1-F2 and, given the unknown nature of their regulation, that 
one of the regions could promote PB1-F2 translation while the other inhibits PB1-F2 
translation. One possibility is that one or both of these regions could be affecting a 
previously predicted psuedoknot which incorporates the PB1-F2 start codon by either 
stabilizing the structure to aid in translation at the PB1-F2 start codon or by inhibiting the 
formation of the pseudoknot to allow the translational machinery to scan past the PB1-F2 
AUG (28). Alternatively, one or both of these regions could be involved in forming a 
novel RNA structure in to the PB1 mRNA. Also, it is possible that one or both of these 
regions interact with PB1, N40, or a host RNA binding protein in order to facilitate PB1-
F2 translational regulation. Thus, a significant amount of work remains in order to 
understand this novel bi-partite regulation motif. 
Though we do not understand the mechanism of how these translational regulatory 
regions contribute to PB1-F2 expression, they still may be useful as a tool for predicting 
PB1-F2 expression. As we have illustrated, the F2 ORF and 3ʹ PB1 regions described 
here can be interchanged to modify the level of PB1-F2 expression (Fig. 6 and Fig. 7). 
Therefore, using RNA sequences from the F2 ORF and 3ʹ PB1 regions of known PB1-F2 
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expressing viruses for comparison with viruses of unknown PB1-F2 expression may 
allow for better prediction of biologically relevant PB1-F2 expression. Studies are 
currently underway to narrow the minimal RNA sequences necessary and sufficient for 
regulation of PB1-F2 in multiple virus strain backgrounds so that accurate predictions of 
PB1-F2 expression may be possible. 
It is unclear why the full PB1-F2 ORF would be maintained in some swine origin 
IAV, yet these viruses contain regulatory sequences that result in such low expression 
levels of the protein in infected cells. It is possible that PB1-F2 expression is either 
unnecessary or deleterious for productive infection in the swine host and has therefore 
been lost either through truncation or through this novel translational regulatory 
mechanism. Nonetheless, spillover between swine and human adapted viruses are not 
infrequent events, and it will be important to further determine both the sequence 
determinants involved in expression of swine origin PB1-F2, and the consequences of 
that expression. Utilizing data from this work, future experiments will include creating 
recombinant viruses that express swine origin PB1-F2 at biologically significant levels 
such that the molecular function and pathogenic impact of the protein encoded by these 
viruses can be fully investigated.  
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CHAPTER 5. OTHER CONTRIBUTIONS TOWARDS 
UNDERSTANDING PB1-F2 TRANSLATION DURING INFLUENZA 
INFECTION 
INTRODUCTION 
 To further study the translational regulation of PB1-F2 during infection with 
swine and human influenza A viruses (IAV), the development of additional tools will be 
necessary. As illustrated in chapter 4, we have determined using a translational clone 
system that nucleotide sequences in the PB1-F2 ORF and the 3ʹ region of PB1 can 
regulate translation of PB1-F2. In order to further confirm this we are in the process of 
developing recombinant viruses to confirm our findings in a viral system. Additionally, 
we are also in the process of developing a NanoLuc luciferase transgenic expression 
system to quantify PB1-F2 translation using the different sequence motifs and to develop 
more of an understanding on how the translational elements effect PB1-F2 regulation. 
This chapter will discuss both of these techniques, the questions we hope to answer using 
them, and the progress that has been made thus far with each of them. 
MUTATION OF REGULATORY ELEMENTS OF PB1 IN A VIRAL SYSTEM 
TO VERIFY RESULTS IN MODIFICATION OF PB1-F2 EXPRESSION 
 To verify our results we will develop recombinant viruses  using PB1 plasmids 
similar to the MOMF2up/3xFLAG and PR8F2dwn/3xFLAG translation plasmids, 
described in chapter 4. We determined that in order to develop these recombinant viruses 
it is necessary to remove the 3xFLAG epitope tag as it appears to interfere with rescue of 
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viable influenza virus. The plasmids created for this purpose have been named 
MOMF2up/PB1 and PR8F2dwn/PB1. Upon successful rescue of recombinant viruses we 
would use the PB1-F2 antibodies described in Chapter 4 to determine the translation 
levels of PB1-F2 in infection. Though the process in theory sounds simple there is the 
potential for complications. Since we are modifying fairly sizable portions of the PB1 
gene, nucleotides 267-343 and 582-816, there is a potential of affecting the polymerase 
and RNA recognition activities of the PB1 protein either through direct modification or 
through affecting the overall structure of the protein. Affecting these functions with the 
PB1 protein could have dire consequences on the viral life cycle and result in the creation 
of either non-viable virus or replication deficient virus. If rescue of a virus that is 
attenuated by the PB1 modification it would be difficult to say what effects that would 
have on PB1-F2 expression. 
Plasmid creation. MOMF2up/PB1 and PR8F2dwn/PB1 uses plasmids were generated 
previously described in chapter 4. MOMF2up/PB1 was created using PCR products 
containing the 5ʹ PB1 and F2 ORF regions from MO(P267-335)O(P392-816)M/3xFLAG 
and nucleotides 336-581 from the 3ʹ PB1 region from MOM/PB1 and inserted into 
MPM(P392-816)M/3xFLAG via triple ligation using BsaAI, EcoRI, and BsmBI sites. 
PR8F2dwn/3xFlag and pHW2000/PR8/PB1 were used as templates for overlap PCR and 
the resulting product was inserted into PR8F2dwn/3xFlag using BstAPI and BfuAI sites 
to create PR8F2dwn/PB1. 
Current progress. Both plasmids have been created and confirmed using sequencing. 
Using the reverse genetics protocol described in chapter 4,viruses encoding the 
MOMF2up/PB1 gene have been created using the other seven plasmids from the Mx09 
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and PR8 reverse genetic systems(rMx/MOMF2dwn and rPR8/MOMF2dwn), both 
confirmed by sequencing RT-PCR products. Using these viruses and the previously 
described immunofluorescence protocol (Chapter 4) we confirmed that the PB1-F2 
protein is expressed at slightly higher levels but the viral life cycle and kinetics of PB1-
F2 expression has been effected. Changes in the viral life cycle were observed through 
differences in NP staining of infected cells at 12 h p.i. which is normally dispersed 
throughout the cell, but in the MOMF2up/PB1 mutants NP localization was primarily 
localized to the nucleus. Additionally, in order to detect and measure PB1-F2 expression 
it was necessary to perform the assays at 24 h p.i. instead of 12 h p.i. Using 
rMX/MOMF2up and rPR8/MOMF2up we detected PB1-F2 expression at 2.9% and 
3.9%, respectively, an increase over swine-like PB1-F2 expression by six to eight fold. 
Showing that an increase in expression of PB1-F2 in the viral system is possible, but 
either as a result of mutations to the PB1 or other factors in infection the PB1-F2 
expression levels has not quite reached PR8 PB1-F2 expression levels in viral infection.  
 Currently the reverse genetics process for viruses encoding the PR8F2dwn/PB1 is 
underway. Once completed the results will be compared with those from the 
MOMF2up/PB1 mutants, but at the time of writing this thesis viruses encoding the 
PR8F2dwn/PB1 gene have not been confirmed. 
CREATION OF A NANOLUC PB1-F2 TRANSGENIC EXPRESSION SYSTEM 
 In order to further confirm that the regions within nucleotides 267-343 and 582-
816 were part of a translational element we wanted to design a transgenic expression 
system to see if we could remove these translational elements and use them to regulate 
translation in the context of another protein. To do this we replaced the portion of PB1-F2 
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that was not essential for translational regulation with the sequence encoding NanoLuc 
luciferase (Promega). Developed by Promega the NanoLuc luciferase system offered a 
number benefits we wanted to take advantage of including: small reporter gene size and 
high level of sensitivity (1). The size is important because we are concerned that 
increasing the number of nucleic acids within the expressed protein may inhibit the 
function of the translational elements. Using the NanoLuc pNL 3.1 plasmid (Promega), 
the NanoLuc (Nluc) gene was amplified using gene specific primers and in inserted it 
into pCi-Neo using MluI and SalI restriction enzymes to create pNeo-Nluc. We intend to 
amplify the sequences between nucleotides 267-816 of MOM/3xFLAG and 
MOMF2up/3xFLAG and clone them into Neo-Nluc fusing the C-terminal portion of 
PB1-F2 directly with the Nanoluc in order to create Neo-Nluc/MOM and Neo-
Nluc/MOMF2up. These plasmids with the Neo-Nluc will be used in luciferase assays to 
determine if the translational elements effect translation independent of their secondary 
open reading frame (sORF) orientation. Further plasmids will be created by inserting the 
5ʹ PB1 portion of pHW2000/Mx09/PB1 directly before the NLuc start codon of either 
Neo-Nluc/MOM or Neo-Nluc/MOMF2up to create Neo-Mx/Nluc/MOM or Neo-
Mx/Nluc/MOMF2up, respectively. This will reestablish the Nluc/PB1-F2 fusions into a 
sORF orientation allowing us determine if the translational elements sequences can affect 
sORF gene expression independent of PB1-F2 expression. If complications arise and the 
NanoLuc luciferase system does not work, we can alternatively substitute the 
nonessential nucleotides of PB1-F2 with a partial sequence of another protein, such as 
GFP. 
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CHAPTER 6. GENERAL CONCLUSIONS 
 In thesis, we described two different projects that were targeted at the same goal 
of increasing our knowledge and understanding of influenza IAV infection in pigs at 
diagnostic and basic biology levels. The first project looked at the developing diagnostic 
tools for the serological detection of HPAI H5N1. Using pigs that were vaccinated with 
one of three rH5N1 viruses, we determined that hemagglutinin inhibition assays were 
limited in the ability to detect antibodies for the rH5N1 viruses and that depending on the 
viral strain, the antibody titers could be reported several fold lower than if the 
homologous viruses were used for the assays instead. As these were immunized rather 
than naturally exposed pigs, the homologous HI titers were likely several fold higher than 
what would be detected in infected pigs, making the fold-decrease in the cross-HI assays 
significant for detection of H5 antibodies in pigs in the fields. Additionally, we 
determined that developing ELISAs using recombinant HA protein would be preferential 
to whole virus antigen for H5N1 specific ELISAs because of increased specificity with 
the assay. The information gained from this project should provide a number of 
considerations when developing methods for detecting the prevalence of H5N1 
antibodies in swine populations. 
 In the second study, we focused our study on understanding the virulence factor 
PB1-F2 in endemic swine IAVs. We determined that, unlike a number of the previously 
published PB1-F2 proteins, that the PB1-F2 protein in swine IAV is expressed at 
significantly lower levels during swine IAV infection. Using translation clones we went 
on to determine that PB1-F2 translation is regulated by sequences located in the PB1 
mRNA located between nucleotides 267-343 and 582-816. Currently, active and future 
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experiments will go on to confirm and elaborate on the finds described in this project.  
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